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AN ADAPTIVE TWO-STAGE DOSE-RESPONSE DESIGN METHOD FOR
ESTABLISHING PROOF OF CONCEPT IN DRUG DEVELOPMENT
Yoko Tanaka, PhD
University of Pittsburgh, 2010
In clinical drug development, searching for the true dose-response curve is ethically and
logistically challenging. Establishing evidence of dose-response or Proof of Concept (PoC) is
the first step for both determining the best dose-response model and optimizing a treatment
dose correctly for clinical use. To overcome these challenges, we employ an adaptive two-
stage design where both adding and dropping treatment arms is possible between stages. In
the first part of this dissertation, we develop a method extending the Multiple Comparison
Procedures and Modeling (MCP-Mod) approach into this adaptive two-stage design. Our
goal is to establish ”global” PoC across the stages. Between stages, we propose using an
Adding and/or Dropping Treatment Adaptation Rule (ADTAR). In the ADTAR method,
dose specifications in the second stage depend on the first stage’s results. Treating the
unobserved doses and imbalanced aggregate sample sizes in the second stage as missing
data, we derive weights and adjust the test statistics in the second stage. Specifically, we
assume that the missing data mechanism caused by ADTAR is missing at random. At the
end of the second stage, we perform the global PoC test combining the test results from both
stages. To preserve the family-wise error rate, we use a Conditional Error Function. Using
simulation studies, we evaluated our design method and compared it to a conventional (one-
stage) study design and different fixed two-stage designs. Our method showed overall robust
high power for detecting the global PoC across three forms of true dose-response curves. In
the second part of this dissertation, we find constraints for choosing doses in the original and
extended MCP-Mod methods. Specifically, we establish lower bounds of the number and
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levels of doses for each method using simulation studies. Our proposed method is a viable
tool in searching for a dose-response relationship. In accordance with ICH guidelines, our
method helps to provide optimal doses of drugs for treating or preventing different diseases.
Since drugs are widely used in human populations, such methods have a great Public Health
impact in appropriately treating or preventing many types of diseases.
Keywords: Adaptive Two-Stage Design, Adding and/or Dropping Treatment Adaptation
Rule (ADTAR), Dose-Response Models, Proof of Concept (PoC), Multiple Comparison
Procedures - Modeling Approach (MCP-Mod), Clinical Drug Development.
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1.0 INTRODUCTION
In recent years, novel designs of clinical trials have played an increasingly important role
in the drug approval process. For example, the use of adaptive designs generally allow for
earlier decisions whether to continue or stop a trial in a combined phase such as Phases
I and II or Phases II and III. The FDA recently released a draft guidance on adaptive
designs and commented that employing adaptive designs in clinical trials is expected to lead
to operational efficiency as well as more informative results given a well-controlled study
setting [13]. In the long run, it is expected to benefit patients who need efficacious and
safety drugs as early as possible.
The term, ‘adaptive design’ has a broad meaning. Gallo, et al. [14] referred to an
adaptive design as being a clinical study design that uses accumulating data to decide how
to modify aspects of the study as it continues without undermining the validity and integrity
of the trial. Other authors such as Chang, et al. [8] cite many types of adaptations such as
adjusting sample size, stopping early due to efficacy or futility, changing the timing and the
number of analyses, etc. A more thorough discussion of such adaptations is given in section
2.3.1.
In the FDA’s draft guidance on adaptive designs, clinical experimenters are encouraged
to detail pre-specified adaptation rules in protocols [13]. The law of Good Clinical Practice
(GCP) [22] requires that a clinical protocol be approved by Institutional Review Boards
(IRBs) and the regulatory agencies prior to performing the clinical trial. If any protocol
amendments are required later on, then that amendment should not be implemented before
being reviewed and approved by IRBs and regulatory agencies. Thus, such review procedures
often delay the clinical trial. When design adaptations are pre-specified in the initial study
protocol, protocol reviewers at the IRBs and regulatory agencies are informed in advance
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of what design aspects will be changed in the course of trial. Hence, in such cases, the
subsequent review procedures could be expedited by the well-informed protocol reviewers.
In clinical drug development, one of the important factors to consider is the nature of a
dose-response (D-R) relationship. A candidate drug is usually brought into the clinical stage
with its preliminary pharmacological, toxicological, and absorption/distribution/metabolis-
m/excretion (ADME) drug profile, which has been characterized by data from the pre-clinical
stage. However, the physiological mechanisms of the human body are not identical with those
of the animals studied in the pre-clinical stages and it is not uncommon that the investi-
gational drug behaves differently than the predicted profile information. Therefore, it is
important to characterize the drug profile in the clinical stage so that a dosage is correctly
optimized for clinical use. Unlike the pre-clinical stage, it is not easy to characterize the en-
tire ADME profile in the clinical stage due to ethical constraints. For example, in a clinical
setting it could be unethical and/or burdensome to observe the relationship between drug
concentrations in plasma and responses because of the necessity of obtaining blood samples.
In contrast, the relationship between dose administration and responses is much easier to
observe in the same setting. Consequently, a D-R relationship is recognized as important
information in order to determine a maximum toxicity dose, a minimum efficacious dose,
and a therapeutic dose window of a drug in its clinical stage.
The International Conference on Harmonization Guideline E4 (ICH-E4) [21] raised an
issue that practical study designs do not exist to allow for precise determination of these
doses. The randomized parallel dose-response study design is extensively used and has
had considerable success among the classical clinical study designs. However, in ICH-E4,
regulatory agencies and drug developers have been encouraged to employ new approaches in
the design and analysis of dose-response data. Accordingly, adaptive dose-response designs
have been one such novel approach of recent use in the pharmaceutical industry.
The Pharmaceutical Innovation Steering Committee (PISC) of the Pharmaceutical Re-
search and Manufacturers of America (PhRMA) formed the Dose-Ranging Designs working
group in 2005, and the group has summarized their work to evaluate and develop alternative
approaches to conventional dose-finding designs including adaptive dose-ranging designs by
Bornkamp, et al. [4]. The multiple comparison-modeling approach (MCP-Mod) by Bretz, et
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al. [6] and Pinheiro, et al. [29] is one of the evaluated approaches. This hybrid methodology
uses both multiple comparison procedures (MCP) and modeling techniques (Mod) within
one strategy for dose-ranging studies. Using the MCP-Mod method, one is able to test if a
dose-response curve is significant. Hence, if this proof of evidence, or proof of concept (PoC)
result, is to be significant, the best dose-response model is selected from a set of multiple
candidate models, and is followed by estimation of target doses within the selected best
model.
In this dissertation, we propose to generalize one previously developed method for two-
stage adaptive designs to accommodate situations where both adding and dropping treatment
arms are possible between stages. Our procedure will be based on using the data set in its
entirety and will control for the familywise error rates. Specifically, we propose the following:
1. to develop an efficient two-stage study design where an adaptation rule adding and/or
dropping treatment arms, which we call ADTAR, is pre-specified;
2. to use our adaptive design to establish evidence of a global dose-response relationship or
Proof of Concept (PoC) for a treatment; and
3. to show that the two-stage design with the pre-specified adaptation rule can be used to
improve statistical power in establishing global PoC.
Our proposed approach extends the MCP-Mod method. We employ the idea of MCP-
Mod to use sets of multiple candidate dose-response models in a two-stage adaptive design,
but we further allow adding new treatment groups and/or dropping inferior treatment groups
in the second stage. At the beginning of the second stage, we prepare the same set of the
candidate dose-response models while using possibly different dose levels. In our study
design, not only is PoC evaluated at the end of the first stage, but we also consider how
to combine data across the two stages to globally establish the PoC while controlling the
family-wise error rate (FWER). Since the ICH-E4 advises drug developers to examining the
entire database for possible dose-response information, the entire dose-response data is used
in our adaptive two-stage study design. We consider detecting a D-R relationship in the
special case of adding and/or dropping treatment groups, and evaluate the power of our
approach compared to that of a common conventional study.
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2.0 KEY LITERATURE REVIEW
2.1 DOSE-RESPONSE MODELS
Let f(d, θ) denote a general steady-state D-R model with a parameter vector, θ, which is
used to describe a mean response at a certain dose level, d. The Emax model is a simple
empirical dose-response model which is applicable to situations where the test drug does not
behave irreversibly and where equilibrium exists between the concentration of the drug at
the effect (e.g., organ) site and in the plasma [9]. Its general form is




where θ = (E0, Emax, EC50), E0 is a baseline effect, Emax is the maximum effect associated
with d, and EC50 is the dose that produces half of the maximum change [5].
When a pharmacokinetic (PK) state is considered to be steady under the same conditions
for the Emax model, logistic models and log-linear models are also commonly used to study
a relationship between a drug concentration and a drug effect [27]. Branson, Pinheiro, and
Bretz [5] used the following logistic model in their development of the MCP-Mod approach:






where E0 is the baseline effect, Emax is the maximum effect size from the baseline effect, EC50
is the dose producing half of Emax, and δ is the parameter related to the rate of response
change with dose. In 2.2, E0 and Emax are location and scale parameters, respectively.
Therefore, its standardized model has the standardized parameter vector, θ∗ = (EC50, δ).
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According to Branson, et al. [5], in this standardized model the effect size increases from
half of Emax to










+ . . .
))−1
Emax ≈ 0.75Emax
as one increases dose from EC50 to EC50 +δ. Another possible model choice is the log-linear
model (Branson, et al. 2003),
f(d, θ) = E0 + δ log(d+ c) , (2.3)
where θ = (E0, δ), and c is a constant which satisfies the inequality, c > −d.
2.2 CLASSICAL DOSE-RESPONSE STUDY DESIGNS
Ruberg [30] discussed classical designs for dose-response studies and related issues. In drug
development, dose-response clinical trials are generally performed to study four aspects of
an investigational drug: 1) to discover evidence of any treatment effect, 2) to find differences
between treatment effects and a placebo effect, 3) to characterize the relationship between
dose and response, and 4) to choose the optimal dose. To achieve these objectives, two an-
alytic approaches, ANOVA and regression modeling, are commonly used in classical clinical
study designs.
ANOVA is more suitable for objectives 1) and 2), and contrast tests or multiple compari-
son tests are embedded when we have multiple doses and a placebo group. For example, when
an alternative hypothesis to test the hypothesis associated with objective 1) is constructed
specifically as the ordered mean responses with at least one inequality, the contrast test is
the most powerful. To test differences between treatment effects and a placebo group in 2),
the multiple comparison test is performed in several possible procedures. The most basic
procedure is to compute a test statistic assuming that the test statistic follows k-variate ana-
log to student’s t-distribution for the k treatment groups under the null hypothesis. Both
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step-down and step-up procedures are available to modify the procedure if needed. The
step-down procedures construct multiple null hypotheses so that a higher dose or a higher
response are tested first. The next higher dose or response are tested only when the former
null hypothesis is rejected. This step is repeated in a descending order until a certain null
hypothesis is accepted. The step-up procedures take reverse steps starting with a lower dose
or response against the step-down procedures. The step-up procedures proceed the next
hypothesis testing when a null hypothesis is accepted and stop when a null hypothesis is
rejected. In both step-down and step-up procedures, the overall type I error for the mul-
tiple comparisons is controlled and hence, estimating an minimum efficacious dose (MED)
to satisfy objective 4) is possible. The step-up procedures are more powerful than the step-
down procedures when more doses are effective. However, in terms of increasing power, the
single-step procedures appear to be better options as they utilize all dose information about
possible response patterns in contrast to tests with k-multivariate t-statistics.
A regression modeling approach is useful for objective 3) characterizing the relationship
between dose and response; and objective 4) choosing the optimal dose. The popular Emax
models were previously described. Since we assume that the underlying dose is continuous in
the model, it is possible to estimate the confidence intervals for the optimal dose. Parenthet-
ically, it is not necessary to assume equal variances of the population response at each dose.
Finally, by evaluating model fit, a best response curve function can be selected. However, it
is not always easy to specify the functional form of a model. Furthermore, it may be difficult
to differentiate a target dose from other doses if the confidence intervals for the optimal dose
are relatively wide.
The International Conference on Harmonization Guideline E4 (ICH-E4) [21] reviewed
four classical study designs for dose-response clinical trials. Placebo controlled, randomized
parallel dose-response clinical trials are the most common classical designs where subjects
are randomized into several treatment dose groups or a placebo group. Since these types
of studies are designed to reduce confounding factors as much as possible, the analytic ap-
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proaches are usually simple and treatment differences are easily evaluated. With a placebo
group, a trend in response can be analyzed over a dose range. The ICH-E4 [21] commented
that one disadvantage is that only a population-averaged dose-response curve can be stud-
ied because individuals do not have their own placebo control data. They also recommend
the use of large sample sizes to increase the precision in the estimate of a treatment effect.
When a combination therapy with more than one drug need to be analyzed, a special case
of placebo-controlled designs called Factorial designs is useful.
Forced titration studies and optional titration (placebo-controlled titration to end-point)
studies are designed so that each subject receives several different doses sequentially until
they reach a certain fixed dose or a target response. Regardless of how the dose-response
is established analytically, it is difficult to determine whether the desired dose-response oc-
curred due to a delayed (carryover) effect or due to an immediate effect because of the
optimal accumulation of the plasma concentration of the drug.
Cross-over dose-response study designs overcome the disadvantage of the placebo-
controlled randomized parallel designs and usually use smaller sample sizes. In typical Latin
squares designs, subjects are randomized to several doses. After a short period of time to
wash-out carryover effects, they are assigned to different doses. This procedure is repeated
until all subjects experience all different doses. Both population-averaged and individual
dose-response curves can be evaluated but uncertainty may remain in terms of carryover
effects, baseline comparability after the first period, and period-by-treatment interactions.
Also the analyses may be not simple when some subjects withdraw in the middle of a study.
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2.3 ADAPTIVE DOSE-RESPONSE STUDY DESIGNS
2.3.1 Adaptive Designs
Gallo, et al. [14] defined adaptive design as a clinical study design that uses accumulating
data to decide how to modify aspects of the study as it continues without undermining the
validity and integrity of the trial. Golub [16] commented that advantages of adaptive clinical
trials are that 1) one can adopt modifications of a study design if the interim data is reliable,
and 2) one can avoid possibly underpowered or uninformative conclusions. Hence, by de-
sign, clinical trials can be more effectively operated and correct estimates for arriving at the
conclusions of a study can be obtained with minimal operational bias. Consequently, adap-
tive designs may be superior to classical designs in terms of achieving scientific conclusions
rapidly while still maintaining study integrity [10]. on optimizing the operating character-
istics associated with such designs. For example, Koyama, et al. [24] developed a technique
to optimize two-stage adaptive designs and concluded that the three most influential design
components in Stage 1 are the sample size, and the type I and II error rates.
There are many ways that an investigator can choose to adapt a study design. Chang,
et al. [8] listed ten different adaptations as 1) adjusting sample size, 2) stopping early due to
efficacy or futility, 3) changing the timing and the number of analyses, 4) dropping inferior
treatment groups, 5) adding new treatment groups, 6) response-adaptive randomization, 7)
modifying the target population, 8) changing study endpoint, 9) treatment switching, and
10) any combination of the other adaptations. Dragalin [11] and Bornkamp [4] classified
adaptive designs into five major trial categories in terms of treatment arms and trial char-
acteristics: single-arm trials, two-arm trials, multiple-arm trials, seamless design trials, and
dose-finding trials. These categories are associated with drug development phases where
particular classified designs are typically used.
In single-arm trials, only one treatment group is studied. These trials are often per-
formed as Phase I clinical trials in drug development. Phase I is the first stage where a new
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investigational drug is studied in humans for its safety, metabolism, and pharmacology eval-
uations. There are two types of adaptive single-arm designs: two-stage designs and screening
designs. Two-stage adaptive designs are the studies where a single treatment group is studied
over two stages to test if a drug shows a certain probability of response. Between the stages,
an interim analysis is performed and the design is modified according to a pre-specified rule.
An early stopping rule for futility and adaptive sampling are the common modifications, and
the designs are also seen in Phase II trials. Screening designs are the designs which are mod-
ified over the entire drug screening process. The screening designs can be used to identify
the most potentially efficacious drug(s) within a shortest time by design modifications.
In two-arm trials, one group is usually called the treatment (experimental) group and
the other is a placebo (control) group. The two-arm trials are usually used as Phase II or
Phase III clinical trials. In Phase II, preliminary data on drug efficacy are obtained in a
target patient population. Study confounders are well-controlled with relatively small-scaled
sample sizes. Phase III trials are called confirmatory studies, which are expanded controlled
or uncontrolled, and additional information about drug efficacy and safety are evaluated with
large-scaled sample sizes. Typical two-arm trials are group sequential designs and adaptive
group sequential designs. Group sequential designs consist of two or more cohort stages and
a stopping rule is applied for the preliminary result of each interim analysis between stages.
With pre-specified stopping boundaries, there is an opportunity to make an early decision
about going to the next stage or not at each step. Such boundaries are usually associated
with hypothesis testings on clinically beneficial response and the overall type I error rate
can be controlled. The group sequential designs are seen in Phase I stage as well. Adaptive
group sequential designs are extensions of the group sequential designs which use a stopping
rule for individual subjects instead of cohort group units.
In multiple-arm trials, more than two treatment groups are studied often in Phase II
settings. Since the trial objectives are often finding a clinically efficacious trend over doses
and selecting the optimal dose for a clinically beneficial effect, their roles can be a part of
9
dose-finding trials. Three types of adaptive designs, Bayesian designs, pairwise comparisons
with group sequential designs, and flexible designs, are used in multiple-arm trials. Bayesian
designs are used to make a decision about stopping or continuing the studies at the interim
analyses based on either the posterior distribution of the parameters of interest or the es-
timated losses of discontinuation. Pairwise comparisons with group sequential designs are
the group sequential designs where multiple treatment groups are compared with a placebo
group by controlling the overall type I error. It is possible to adaptively drop some treat-
ment arms due to inferior outcomes. Flexible designs are two-stage designs where multiple
comparisons are performed in each stage and the results of the two stages are combined to
test an overall hypothesis by controlling the familywise type I error rate. The advantage
of the designs is to allow many types of adaptations such as sample size adjustment, early
stopping, changing endpoint, and adding or dropping treatment arms.
Seamless design trials are used across two phases of drug development, that is, across
Phase I and II, or, alternatively, across late Phase II and Phase III, to combine different trial
aims within one protocol. Since it is possible to use more consistent operational systems with
one protocol comparing with two separate protocols, operational biases are expected to be
reduced. An example of adaptive designs within this category is the learning/confirmatory
design in Phase II/III. Learning/confirmatory designs in Phase II/III combine a Phase II
trial to explore a drug efficacy with multiple doses and possibly with secondary outcome,
which can be observed quickly, and a Phase III trial to confirm the Phase II result with a
primary outcome. When they are performed in one protocol, the overall type I error is to
be controlled.
In the dose-finding trials, the main goal is to find a best dose to be used in the following
confirmatory trials according to a pre-specified criterion. The selected dose is manufactured
in a much larger scale and the clinical data are to be collected for the selected dose in the
following studies. Thus, dose-finding is an important step in drug development. The next
subsection details the adaptive designs classified into this category.
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2.3.2 Adaptive Dose-Response Designs
Adaptive dose-response studies can employ broad modifications including adjusting sample
size, stopping early due to efficacy or futility, changing the timing and the number of analyses,
dropping inferior treatment groups, adding new treatment groups, and response-adaptive
randomization. According to PISC of PhRMA [4], the general objectives of adaptive D-R
studies are: (1) to show proof of concept; (2) to establish the D-R curve; (3) to select the
optimal dose; and (4) to estimate the therapeutic window. For these objectives, various
approaches for a D-R study have been developed. Typical examples include 1) a Bayesian
adaptive dose allocation approach [3], 2) a D-optimal response-adaptive approach [12], 3) a
multiple comparison procedures-modeling approach (MCP-Mod) [5, 6], 4) a Bayesian model-
averaging approach [4], 5) a multiple trend test approach [4], and 6) a non-parameteric D-R
modeling approach [4]. A brief description of each type of design is given below.
Bayesian adaptive dose allocation approach. In this approach, each new enrolled
subject is assigned to a treatment group or a placebo group according to an allocation rule.
When the next subject is enrolled, all available data at that time including ongoing subject
data is used to select an optimal dose for the subject. The data is also used to update
the estimated dose-response curve. Whether to stop the study or not due to futility or
remarkable efficacy is determined based on the posterior probability of the response at the
optimal dose. Timely data capturing is a challenging issue and the frequent access to the
available data by sponsors or physicians can cause significant biases. Relatively large biases
in target dose estimation have been shown to be present as demonstrated by the simulation
study by PISC of PhRMA [4] when the number of treatment groups was large.
D-optimal response-adaptive approach. In a group sequential adaptive design, the
D-optimal allocation rule is sometimes used. The D-optimal algorithm determines an alloca-
tion ratio by minimizing the variance of dose-response model parameters at the completion
of each study cohort. At the end of the study, the final dose-response curve estimation and
the optimal dose selection are performed. The study information is maximized by D-optimal
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allocation rule. However, because of the characteristics of an allocation rule, the method
may not be best suited for the case where the modification of adding and dropping treatment
arms is forced in a study.
Multiple Comparison Procedures-Modeling approach (MCP-Mod). In this
method, multiple comparison procedures (MCP) and modeling techniques (Mod) are com-
bined within a single study. For the test on the existence of a dose-response curve, a multiple
model candidate set is pre-specified. These models are standardized and used to compute
test statistics assuming that the test statistics follow the multivariate t-distribution under a
null hypothesis and a familywise error rate can be controlled. For the best model selection,
a certain model selection criterion such as BIC is used. After the best dose-response curve
is selected, a target dose is estimated using the selected best model.
Bayesian model-averaging approach. A set of simpler dose-response models are pre-
specified and the individual model weight is calculated based on prior model probabilities.
The posterior distributions on model parameters are updated from the prior distributions of
the parameters using Markov Chain-Monte Carlo for each model. The models are averaged
by the weights. This method is useful when the main objective of a dose-response study is
estimating some quantities which are not dependent on the dose-response curve.
Multiple trend test approach. As the class of Emax models can cover various dose-
response curves, the underlying dose-response curve is described by three different Emax
models called lower, middle, and upper Emax models. The middle curve is chosen so that the
differences in power of the three trend tests can be minimized. The maximized likelihood is
used to estimate the dose-response curve, and the inverse regression method on the estimated
curve is used to estimate the target dose for a pre-specified clinically significant effect. Since
the target dose is not the attribute of the model, it may not be able to identify for the
pre-specified and selected dose-response curve. The simulation result by PISC of PhRMA
[4] implied that the design could misguide us to a further clinical trial when there is no
significant evidence of a treatment response.
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Non-parameteric dose-response modeling approach. This is a non-parametric
regression modeling method using local polynomials (LOESS). As for the estimation of the
dose-response effect, a multiple contrast test is used. A target dose is estimated using local
quadratic regression or smoothing techniques. In the study by PISC of PhRMA [4], the
estimation of target doses was not be so powerful as MCP-Mod. Also, the interpretation of
the dose-response curve may not be straightforward.
Among these approaches, the first (Bayesian adaptive dose allocation approach) and
second approaches (D-optimal response-adaptive approach) use adaptive designs where one
is allowed to modify design aspects while a trial is performed in either a continuous or in a
group-sequential manner. In contrast, the remaining four approaches have flexibility in the
procedures of analysis but do not use an adaptive design.
2.4 MULTIPLE COMPARISON PROCEDURES-MODELING METHOD
The MCP-Mod approach by Branson, et al. [5] and Bretz, et al. [6] allows one to make
three different decisions within a dose-finding study, (i) a proof of concept (PoC) that the
treatment is effective, (ii) the best D-R relationship, and (iii) a choice of dose(s) to use in
further development. In the establishment of PoC, a set of unnested candidate models which
cover a suitable range of dose-response shapes is used instead of a pre-specified single dose-
response model. Each candidate model is assessed by an optimally chosen contrast test and
multiple comparison procedures (MCPs) are employed to combine model results in order to
control the family-wise error rate (FWER). If PoC has been established, the best model is
selected (Mod) from the statistically significant models in the candidate set. Furthermore,
the selected D-R model is used to estimate a target dose for clinical use. We will now give
a more detailed description of the individual steps.
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The MCP step is necessary for the establishment of PoC. Branson, et al. and Bretz et
al. assume that responses are observed for a given set of parallel groups of patients random-
ized to placebo, d0, and k treatment doses, d1, d2, ..., dk. Suppose that one considers the
following D-R model specification:
yij = f(di, θ) + ij, i = 0, 1, . . . , k; j = 1, . . . , ni , (2.4)
where for the jth subject in the ith group, yij is the response of the subject, di is the dose the
subject receives, f(di, θ) is the mean response of the group given a certain D-R model, f(·),
with a parameter vector, θ, and ij is the independent normal error. f(·) is standardized by
reparameterizing the vector, θ into θ∗. Furthermore, a location parameter, θ0, and a scale
parameter, θ1 are incorporated as follows:
f(di, θ) = θ0 + θ1 f
0(di, θ
∗) , (2.5)
where f 0(d, θ∗) denotes a suitably standardized model. The test statistics are defined by
optimal contrasts. Using such statistics, one can decide which D-R models give us statisti-
cally significant fits. Specifically, suppose that one pre-specifies a setM of M parameterized
candidate models, fm(di, θ), m = 1, . . . ,M , and that each model is standardized. Each D-R
shape can be tested by a single contrast test associated with optimized coefficients obtained
from each standardized model (see Branson, et al. and Bretz et al.). These coefficients are
chosen in advance to maximize the power of the test when the true underlying mean response















N−k−1 , N =
∑k
i=0ni, and cmo, . . . , cmk are the optimal contrasts for
model m. The contrasts are chosen to satisfy
∑k
i=0cmi = 0. The MCP to test whether or not
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there is a dose-response is based on the maximum of T1, . . . , TM via these standardized mod-
els. To control the FWER, the multiplicity adjusted p-value and critical values can be nu-
merically computed based on the assumption that the multiple test statistics, (T1, . . . , TM)
′,
are jointly multivariate t-distributed under the null hypothesis of no dose-response with cor-
relation matrix determined by the model contrasts. If the adjusted p-value is smaller than a
pre-chosen significant level α, then one rejects the null hypothesis and establishes the PoC.
If the null hypothesis cannot be rejected, then the procedure stops indicating that a D-R
relationship cannot be established from the observed data. The MCP is useful because it
accounts for the uncertainty of model specifications at the beginning of the trial.
Once the PoC is established, the model and dose selection is performed in the Mod step.
After the controlled PoC tests, one takes statistically significant models from the candidate
model set,M. The best model is selected from these significant models based on its having
the minimum p-value of the contrast test statistic. Other model selection criteria such as the
Akaike Information Criterion (AIC) or the Bayesian Information Criterion (BIC) can also
be used. As described in Bretz, et al. [6] the selected D-R model is used to estimate a target
dose via inverse regression techniques, typically incorporating information about clinically
relevant effects.
2.5 MODIFICATION OF ADDING AND/OR DROPPING TREATMENT
ARMS IN ADAPTIVE DESIGNS
Phillips [28] commented that the flexibility in adding treatment arms or dropping treatment
arms based on efficacy or safety information is generally acceptable and considered to be
advantageous. The biggest concerns are how to control the overall type I error and how
to estimate confidence intervals. Additionally, in a dose-response study, how to integrate
dose-response modeling in an adaptive design is another issue.
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Both Hung, et al. [19] and Hommel [18] discussed the modification of dropping arm(s) and
overall type I error in terms of testing an effective treatment dose. Hung et al. commented
that it may be advisable to redistribute the unused sample size of the dropped arms to the
rest of the retained arms. This may allow one to increase statistical power in detecting an
effective dose. For establishing PoC, on the other hand, to our knowledge, there is not much
discussion on dropping and/or adding arms. We employ the idea of sample redistribution
for testing PoC in our adaptive design and evaluate if power is retained or improved from
fixed designs of the same total sample sizes via simulations in Section 3.4.
2.6 CONDITIONAL ERROR FUNCTION
Employing the adaptive test procedure by Bauer and Ko¨hne [2], Bretz, et al. [7] concep-
tualized the use of combination tests in the ‘seamless’ Phase II/III adaptive trials where a
conditional error function (CEF) is applied. ‘Seamless’ is usually used to describe the adap-
tive designs that combine two trials of two phases into one protocol. CEF is defined as the
probability of rejecting a global null hypothesis given the p-value of Stage 1 in a two-stage
adaptive design.
A decision rule for rejecting the global null hypothesis of group i, Hg, can be formulated
using the CEF of the combination test as follows:
reject Hg if p2 < A(p1);
A(p1) = PH(reject H|p1) =

1 if p1 ≤ α1
0 if p1 ≥ α0
max{p2|C(p1, p2) ≤ Cα} if p1 ∈ (α1;α0)
(2.7)
where p1 and p2 are the p-values from testing the null hypotheses in Stage 1 and Stage 2,
respectively. Also, α0 and α1 are the stopping boundaries at the interim analysis for futility
and efficacy, respectively, and Cα is a pre-chosen critical value at some α level.
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The above CEF, A(p1), is useful for combining any kind of statistics when one specifies the
function form of its combination test, C(p1, p2). A combination function which is commonly
used in practice employs the weighted inverse normal method, that is,
C(p1, p2) = 1− Φ[ω1Φ−1(1− p1) + ω2Φ−1(1− p2)] where ω21 + ω22 = 1 and ω1, ω2 > 0
[15]. In order to use this method, one must pre-specify weights. An alternative choice is
Fisher’s combination test as discussed in Bauer and Kieser [1]. We follow their method and
test the same set of pre-specified candidate models in both stages, meeting their assumptions.
Fisher’s combination test given by
C(p1, p2) = p1p2 ≤ Cα =
exp(−χ24,1−α)
2
uses a χ2-statistic for the pooled two-stage data which is equal to X 2 = ∑2j=1X 2j =
−∑2j=1 ln pj [15]. In this test, it is assumed that both p1 and p2|p1 follow the uniform
distribution (0, 1) under the null hypotheses in Stage 1 and Stage 2, respectively. The gen-
eral concept of Bretz, et al. can be applied for a global establishment of PoC in a two-stage
dose adaptive design with an adding and/or dropping treatment adaptation rule as well. In
the establishment of the PoC, the hypothesis tests use optimal model contrasts.
The PISC of PhRMA [4] studied the power of each design with respect to the gen-
eral objectives of dose-response studies. We hypothesized that, if design modifications are
introduced to the analytically flexible approaches, we may improve statistical power. We
introduce a design modification into one of the analytically flexible approaches and aim to
gain better power for establishing PoC. Considering that Bayesian approaches are not cur-
rently preferred in drug trials [19], we consider modifying the design in one of the frequentist
approaches. We will discuss the details of our approach in the next chapter.
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3.0 EXTENDED MULTIPLE COMPARISON PROCEDURES AND
MODELING APPROACH
Our methodology extends the MCP-Mod method from a classical one-stage design into a two-
stage adaptive design under an adding and/or dropping treatment adaptation rule (ADTAR)
in order to establish global PoC. We combine the results of the preliminary PoC test in Stage
1 and the adaptive PoC test in Stage 2. The contrast test statistics of Stage 2 are adjusted
using weights which are computed according to the ADTAR in Stage 2. To combine the
results of two stages, we apply the conditional error function (CEF) reviewed in Section 2.6.
3.1 METHODOLOGY
3.1.1 Overview
Our extended MCP-Mod method, Ex-MCP-Mod, has two major features. The first feature
is that through ADTAR, candidate dose combination choices for Stage 2 are pre-specified
and we adaptively select one dose combination based on the result of Stage 1. From a
statistical point of view, ADTAR allows us to pre-formulate all candidate null hypotheses
in the protocol for the PoC test of Stage 2, and we adaptively select one null hypothesis for
Stage 2 after Stage 1 is performed. This pre-specification follows the recommendation of the
FDA’s draft guidance [13] as well.
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The second feature is that ADTAR does not necessarily associate the same number of
potential results of Stage 1 to each candidate dose combination in Stage 2. Therefore, even
though one trial run assigns equal sample sizes to each adaptation choice, over many trial
runs one can end up with different aggregate sample sizes in different adaptation choices
and dose groups. We model this issue as missing data mechanism in Stage 2 and apply
a weighting method for the Stage 2’s contrast test statistics to compensate the effect of
imbalanced sample allocation.
With these features, we aim to improve design power in the global PoC test over con-
ventional and fixed two-stage designs. Statistical power of the Ex-MCP-Mod and the latter
designs is evaluated for four different dose-response patterns through our simulation studies
in Section 3.4. The Ex-MCP-Mod is shown to be a more robust method for establishing
global PoC.
3.1.2 Adding and/or Dropping Treatment Adaptation Rule (ADTAR)
First, we mathematically describe the ADTAR. In the trial design, suppose that there are
M candidate D-R models, f1, . . . , fM , and k potential doses. In Stage 1, we pre-specify
treatment doses to use from k doses. In Stage 2, treatment doses will be adaptively selected
from k doses based on the ADTAR. A placebo group, d0, is always used throughout the trial.
When we apply the PoC step of the MCP-Mod in Stage 1, each D-R model will be either
significant or non-significant in the preliminary PoC test. Hence, a ‘result’ is associated
with a M -vector consisting of 0’s and 1’s where 1 denotes a significant test result for a
given model. Therefore, K1 = 2M different results are possible for the test in Stage 1. In
Stage 2, if we do not count the possible adaptation with no treatment doses, then there are
K2 = 2k − 1 possible sets of dose that could be examined in this stage. Using an ADTAR,
we may associate some of the possible PoC results in Stage 1 with one of the adaptive dose
combinations in Stage 2. Suppose that, under an ADTAR, we specify a set of L adaptation
choices, A = {a1, . . . , aL} where aj denotes choice j. Each of L adaptations is pre-specified
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from K∗2 ≤ K2 possibilities. We denote b as one potential result in Stage 1 and B as the







BL according to the L adaptations, where Bi
⋂
Bj = ∅ for i 6= j. `j
potential PoC results in Stage 1 are associated with the jth adaptation choice, aj, so that∑L
j=1 `j = K1. ADTAR is defined by an adaptation function, g : B −→ A. We show that a
pre-specified ADTAR in a two-stage adaptive design helps to control the FWER in a global
PoC test in Section 3.3.
Test statistics for Stage 1 and Stage 2 can be obtained using the same procedure as in the
MCP-Mod method. Recall from Section 2.4 that the original MCP-Mod method assumed
that the multiple test statistics, (T1, . . . , TM)
′ as defined in 2.4, are jointly multivariate t-
distributed under the null hypothesis of no dose-response. Next we discuss the same approach
in two-stage designs. Let (Ts,1, . . . , Ts,M)
′ denote a vector of the contrast test statistics in
Stage s (s = 1, 2). Further, let MVTM,νs denote a M -dimensional multivariate t-distribution
with νs degrees of freedom and a numerically computed correlation matrix, Rs = (ρuv)s,




























, 1 ≤ u, v ≤M.
The contrast vectors, cm = (cm0, . . . , cmk2)
′ and c∗m = (c
∗
m0, . . . , c
∗
mk2
)′, are optimal in
Stage 1 and Stage 2, respectively. Recalling that νs = Ns − ks − 1 where Ns is the to-
tal sample size in Stage s and ks is the number of treatment doses in Stage s, then, un-
der the null hypothesis, for Stage 1, (T1,1, . . . , T1,M)
′ ∼ MVTM,ν1(0,R1), and for Stage 2,
(T2,1, . . . , T2,M |aj)′ ∼ MVTM,ν2(0,R2). In summary, in both Stage 1 and Stage 2 given a
selected adaptation choice, we can apply the MCP-Mod method based on the same assump-
tion. In the following section, we show how to treat the dependency of Stage 2 on Stage 1
by modeling imbalanced aggregate sample sizes in Stage 2 as missing data mechanism.
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3.1.3 Modeling Stage 2 through Missing Data Analysis
If an ADTAR is used in a two-stage design, then Stage 2 depends on the function g which
uses a result b ∈ Bj to construct the choice of adaptation aj. Across multiple trials, some
doses may not be sampled in each trial’s Stage 2. Hence, over multiple trials, the aggregate
samples for different doses in Stage 2 could be imbalanced depending on both the result in
Stage 1 and the subsequent adaptation employed. In our setting, we can view the adaptation
for Stage 2 as creating a missing data mechanism [25]. Accordingly, the mean estimate for
dose i can be adjusted by applying a missing data analysis method. The missing data
mechanism within Stage 2 is Missing At Random (MAR) because the missingness with
respect to the doses depends only on the observed part of the K1 potential PoC results in
Stage 1. An example illustrating the missing data mechanism is shown in Section 3.4.3.
Since the adaptation choice determines which doses are ‘missing’, we can then condition
on that choice rendering the missing data mechanism as Missing Completely At Random
(MCAR), i.e., quasi-randomized [25]. Under the assumption of quasi-randomization, one
can use the weighting class estimator of missing data analysis. This unbiased estimator uses
the idea that the observations associated with adaptation choice, aj (‘stratum j’ by Little
and Rubin), receive a weight for each dose group, i. We let wij denote the weight which
corresponds to the mean estimate of dose i for adaptation aj. In Section 3.2, we derive the
weights, wij, for dose i and adaptation aj.
Next, we demonstrate how the weights are used in the PoC test statistics in Stage 2.
In our method, at the end of each stage, the PoC step of the MCP-Mod is applied as a
preliminary test (Section 3.1.2). Under the null hypothesis of no dose-response relationship,
the M contrast test statistics jointly follow a multivariate t-distribution in each stage. Since
Stage 2 depends on the ADTAR function, we adjust the contrast test statistics in Stage 2


















N2−k2−1 . Consequently, in Stage 2, the relationship





























and 1 ≤ u, v ≤M . By using the above weighted statistics and correlations, we compensate
the effect of imbalanced sample allocation due to ADTAR.
3.1.4 Combining Stage 1 and Stage 2
In the last step, the same way as in the original MCP-Mod method (Section 2.4), we use
the multiple contrast test statistics and obtain a p-value in each stage by use of multivariate
t-distributions, i.e., (T1,1, . . . , T1,M)
′ ∼ MVTM,ν1(0,R1) in Stage 1 and (T2j,1, . . . , T2j,M)′ ∼
MVTM,ν2(0,R
∗
2) in Stage 2. Let p1 and p2 denote the obtained p-values in Stage 1 and Stage 2,
respectively. In the global PoC test, we plug these p-values into the CEF formula from the
combination technique (Section 2.6) to test the global null hypothesis of no dose-response
relationship. The global PoC is established if p2 < A(p1) =
Cα
p1
where Cα is a pre-chosen
critical value.
3.2 DERIVATION OF WEIGHTS
In this section, we show the derivation of the weight for adjusting the mean response of
dose group i and adaptation choice j in Stage 2 given an adaptive two-stage design with
an ADTAR function. Suppose that we perform a preliminary PoC test using a set of M
candidate dose-response models in Stage 1 and Stage 2, respectively. Let B denote the
set containing all possible PoC results in Stage 1, i.e., B = {b1, . . . , bK1} where K1 = 2M .
Remember that, under the ADTAR, we pre-specify a set of L adaptation choices, A =
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j=1 `j = K1. ADTAR is
defined by an adaptation function, g : B −→ A.
Let yb = (yb0, . . . , ybk) denote a vector of k+ 1 dose responses in Stage 2 associated with
one potential result b, b ∈ B, in Stage 1. Let Y = (ybi). For result b, we define Qbj as the
sample indicator of Stage 2.
Qbj =
 1 if j = g(b),0 otherwise.
Qbj is used to determine the sample set of Stage 2. Let Qj = (Q1j, . . . , QK1j). The dose
adaptation process is characterized by a distribution for Qj given both Y and the adaptive
design information, Z. In order to infer quasi-randomization in Stage 2, the following two
assumptions are required [25]:
1. The distribution of the random indicator variables, Qj, is determined before any values
of Y in Stage 2 are known. Thus, f(Qj|Y,Z) = f(Qj|Z).
2. Every result b has a positive (known) probability of being selected. Hence, if τbj =
E(Qbj|Y,Z) = Pr(Qbj = 1|Y,Z), then τbj > 0 is required for all b.
In this context, our adaptation design matrix Z is a L × (k + 1) matrix indicating the
L adaptation ‘strata’ for the k + 1 doses. Then, both of the assumptions are held and
τbj = E(Qbj|Y,Z) = E(Qbj|Z) = E(Qbj|j = g(b)) = 1. The idea expressed in this equation
is as follows: the probability of j = g(b)) under the condition that j = g(b)) is 1. This
statement is the second condition for using the missing data mechanism. Following Little
and Rubin, the trial is encoded as Z and the ADTAR function g is encoded as Qbj. Using Z
and Qbj, our condition can be expressed as Pr(Qbj = 1|Y,Z). Thus, τbj = 1.
Let Iij be an indicator variable and the ji
th element of the design matrix, Z, such that
Z L×(k+1) = (Iij)′. According to the ADTAR function, Iij is defined as follows.
Iij =
 1 dose group i is included in the adaptation choice j,0 otherwise,
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where i = 0, . . . , k and j = 1, . . . , L. Now, let nb denote the sample size per dose group in
Stage 2 given result b in Stage 1. Furthermore, let n′j denote the population size per dose
group in Stage 2 in stratum j. If equal sample sizes are assumed in Stage 2 and if the total
sample size is N in Stage 2, then n′j =
∑
g−1(j)
nb = `jnb and nb =
N∑k
i=0 Iig(b)
. If result b in
Stage 1 is associated with adaptation aj, for each dose group i a stratified random sampling
takes a simple random sample scheme of nb units from n
′
j population units within stratum j.
In a typical weighting approach, if a unit selected from a target population with probability
pi represents pi−1 units in the population, then the unit should be given the weight pi−1 in
estimates of population quantities. In our particular case, pi−1ij is used as the weight for the
population of dose i in stratum j. In Stage 2, let ϕ−1ib be the weight for a selected unit of







= `j if Iij = 1,
does not exist if Iij = 0,
with j = g(b).
Using ϕib, piij = ϕibτbj. The Horvitz-Thompson weighted estimator of the population total



















i denote our weighting class estimator of mean response
for dose group i, and let y¯ij be the mean response of dose i in adaptation aj in Stage 2.
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3.3 CONTROLLING THE FWER CLOSE TO A PRE-CHOSEN α-LEVEL
‘Strong control of the FWER’ is the concept that the probability of erroneously rejecting a
true null hypothesis does not exceed a pre-chosen confidence level, α, in a multiple level-α
test, irrespective of how many and which are in fact true [1]. Strong control of the FWER is
a useful property for an experimental system using an adaptive two-stage design to be valid.
However, with its performance, there would be a concern that the trial design becomes so
conservative that the statistical power in establishing global PoC gets much lower than we
prefer. In this section we show that a pre-specified ADTAR allows us to control the FWER
close to a pre-chosen α-level in the global PoC test in an adaptive two-stage design.
To construct our proof, we will use a modification of the argument outlined in Bauer
and Kieser [1]. Let p1 be the p-value of an overall PoC test for H0,M in Stage 1, i.e.,
there is no dose-response relationship within the model set, M = {f1, . . . , fM}, in Stage 1.
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Suppose that, to make an adaptation decision, we look at a preliminary PoC result, b ∈
B = {b1, . . . , b2M} in Stage 1. Let G2j ∈ G2 denote a test scenario which employs a specific
distributional assumption. Let G2j be chosen from a finite set of test scenarios, G2, for testing
H0,M in Stage 2. In our two-stage design with ADTAR, the choice of G2j are determined
by both the number of adaptation choices and weights ωij (determined by missing data
mechanism due to ADTAR); the weights are specified based on the selected dose adaptation,
aj ∈ A = {a1, . . . , aL}.
In our setting, we define the adaptation function, g : B −→ A for all candidate models,
in the adaptation protocol. Under H0,M, let pM2 be the p-value of an overall PoC test in
Stage 2 and let h0(p
M
2 |G2j, p1) be the conditional probability density of pM2 in the adaptive
procedure given p1 ∈ (α1, α0) and the choice G2j. If the PoC test under G2j is implemented
in a stochastically independent sample, then pM2 is uniformly distributed on [0,1] for any
given G2j and p1 ∈ (α1, α0). Accordingly, h0(pM2 |G2j, p1) = 1. The detailed proof of this
property is located in the appendix of Bauer and Kieser [1]. The consequence of this property
is that, conditioning on aj, the specification of the overall PoC test in Stage 2 for H0,M is
determined prior to Stage 2, and then, the vector of test statistics, (T2j,1, . . . , T2j,M)
′, based



































, 1 ≤ u, v ≤M,
and ν2 = N2 − k2 − 1, is computed at the end of Stage 2.
Let q0(G2j|p1) denote the conditional probability of choosing G2j given p1. This con-
ditional probability is defined for p1 ∈ (α1, α0). Because p1 is uniformly distributed and
h0(p
M
2 |G2j, p1) = 1, the type I error rate of the overall PoC test for H0,M over the two
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Note that the last inequality holds because the set of testing methods in Stage 2, G2, is
determined by the range of j. aj does not need to cover the full space of all possible PoC
test scenarios and thus is associated with a probability ≤ 1. Therefore, pre-specifying g,
adding and/or dropping of doses, controls the FWER closed to the pre-chosen α-level in an
adaptive two-stage design.
3.4 SIMULATION STUDY: EVALUATING EX-MCP-MOD
To evaluate our approach’s performance for detecting a D-R curve in the proposed design,
we compared it to the one-stage design of the original MCP-Mod method and four fixed
two-stage designs via simulations of 10, 000 trials. To evaluate our missing data weight-
ing procedure, we also compared the proposed design to the same ADTAR design without
weighting via simulations. Figure 1 illustrates the proposed design and compared study
designs. Note that the fixed two-stage designs have two components, Study 1 and Study 2.
Study 1 of each fixed two-stage design is identical to Stage 1 in the adaptive design. Study 2
of each fixed two-stage design is identical to one of the adaptive choices of Stage 2 in the
adaptive design. Then, Study 1 and Study 2 are chosen independently of each other. Overall
performance was measured by quantifying the probability of detecting a D-R curve in 16
different scenarios, which were the combinations of four different models (Emax, Logistic,
Quadratic, and Constant) and four different total sample sizes (N = 80, 200, 400, and 600)
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for each study design. In the proposed design using an example of ADTAR, ADTAR I, the
equal sample sizes for group i in Stage 1 were n1i = 10, 25, 50, and 75. In all the adaptations,
balanced sample sizes for each group in Stage 2 (n2i) were chosen so that the total number
of observations between Stage 1 and Stage 2 would be the same. Note that type I error rates
are merely probabilities of detecting a significant D-R curve under the null hypothesis of a
flat curve. Thus, similar to Branson, et al. [5] and Bretz, et al. [6], we used this assessment
method to evaluate our performance with respect to ‘proof of activity (PoA)’. The common
components of the simulation design and ADTAR I are shown below. We used the same
notation described in Section 3.1.
3.4.1 Simulation Setup
• Data generation: Four datasets were generated based on a population mean vector of
Emax, Logistic, and Quadratic models, respectively. Each model specification was the
same as one of the candidate D-R models. All the models had the property that a
maximum effect size within the interval [0, 1] was 0.8 and that the response at the placebo
was 0.2. The constant data-generating model was f(di) = 0.2. We assumed independent
outcomes from N(f(di), σ
2) at di where σ = 1.478.
• Candidate D-R models: The number of candidate D-R models was three (M = 3). The
model specifications are summarized on Table 1 and Figure 4 where ED50 = 0.2 for f
0
1 ,
δmax = 0.6 for f
0
2 , and ED50 = 0.2 and δ = 0.6 for f
0
3 .
• Doses: The number of potential doses was four (k = 4) as in (d0, d1, d2, d3, d4) =
(0, 0.05, 0.2, 0.6, 1.0).
In Stage 1, (d0, d1, d2, d3) = (0, 0.05, 0.2, 0.6) was used under ADTAR I.
In Stage 2, doses were selected based on ADTAR I described below.
• Significance level: We employed a 2.5 % one-sided significance level to achieve a 95 %
confidence interval in all PoC tests. This is the same confidence interval used in Bretz,
et al. [6]. The mismatch between our significance level and confidence interval is due
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Figure 1: Evaluation: Adaptive Design with ADTAR, Fixed Two-stage Designs, and One-
stage MCP-Mod Design
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to the fact that we used a one-sided test in order to perform the necessary symmetric
two-sided test [5].
• ADTAR I: When ADTAR is required, we used the rule as follows. There were K1 = 2M =
8 possible results in Stage 1 so that B = {b1, . . . , b8}. We let the number of adaptation
choices be four (L = 4) so that the set of adaptations would be A = {a1, . . . , a4} (see
Table 2). We defined the function of ADTAR I, g : B −→ A, as follows:
g :

b1, b2 −→ a1
b4, b6 −→ a2
b7 −→ a3
b3, b5, b8 −→ a4
This ADTAR I does not allow stopping after Stage 1. This implies that α1 = 0
and α0 = 1 in 2.7. For ADTAR I, the contrast weights are computed using 3.3 and
summarized on Table 3.
Table 1: Original and Standardized Model Formula
Model Original formula Standardized formula
f1: Emax f1(d) = E0 +
Emaxd
ED50+d
f 01 (d) =
d
ED50+d
f2: Quadratic f2(d) = E0 + β1d+ β2d

















d ∈ {d0, d1, . . . , d4}
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Figure 2: Standardized Emax (f1), quadratic (f2), and logistic (f3) models.
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Table 2: ADTAR I
Bj b Significant Mod-
els in Stage 1




doses used in Stage 2 balanced sample,
n2i for n1i = 25
(n2i for n1i = 75)
B1 b1 f1, f2, f3 2 a1 d4 d1 d0, d2, d3, d4 25 (75)
b2 f1, f2
B2 b4 f2, f3 2 a2 d4 d3 d0, d1, d2, d4 25 (75)
b6 f2
B3 b7 f3 1 a3 None None d0, d1, d2, d3 25 (75)
B4 b3 f1 f3 3 a4 d4 None d0, d1, d2, d3, d4 20 (60)
b5 f1
b8 None
Table 3: Weights (ωij) Under The Adaptation Choices in ADTAR I










































Simulation Results of all 16 scenarios (four different datasets by four total sample sizes)
are summarized in Table 4 and Table 5 (The R programs for implementing the simulation
studies are available in Appendices A.1, A.2, and A.3). When we italicize, ADTAR I denotes
the proposed adaptive two-stage design. Using the same data, we also evaluated PoA of
ADTAR I without weighting Stage 2’s test statistics. This non-weighting ADTAR design
method is denoted as Non-weighting ADTAR I. Among the four fixed two-stage designs,
Maximum denotes the design with the maximum PoA and Minimum denotes the design with
the minimum PoA, respectively. The one-stage design of the original MCP-Mod method is
denoted as One-stage MCP-Mod. From both Table 4 and Table 5, the FWER seems to be
controlled roughly at a 5% level in all study designs for all total sample sizes. ADTAR I
showed relatively consistent PoA activities across the three different dose-response curves.
Figure 3 shows the global PoA plots of total sample size 200 to compare ADTAR I, Non-
weighting ADTAR I, Maximum, Minimum, and One-stage MCP-Mod for each D-R curve.
The results of these comparisons were similar for all sample sizes considered. That is,
ADTAR I was always more powerful than Non-weighting ADTAR I across the three dose-
response curves. ADTAR I was slightly more powerful than Maximum for the Emax and
logistic dose-response curves. One-stage MCP-Mod also showed higher PoA than Maximum
for the both dose-response curves. However, its PoA for the quadratic dose-response was
lower than Minimum while ADTAR I showed higher PoA than Minimum.
3.4.3 Effect of Sample Size Imbalance across Groups
This section evaluates the sample-compensating effect of weighting based on the missing
data analysis described in Section 3.1.3. As shown in Figure 4a, we consider a hypothetical
case where the eight possible PoC results in Stage 1 (b1, . . . , b8) are equally likely to occur
in a trial using our ADTAR two-stage design. In this example, if the total sample sizes in
33
Table 4: PoAs of ADTARI, Non-weighting ADTARI, One-Stage MCP-Mod, and four two-
stage fixed designs under varying D-R shape × sample size (1)
Design Test n1i/gp Data-Generating Function n1i/gp Data-Generating Function
Choice Stage n2i/gp n2i/gp
(N) Const. Emax Quad. Logist. (N) Const. Emax Quad. Logist.
ADTARI Stage 1 10 0.0369 0.1679 0.2070 0.1811 25 0.0382 0.3207 0.4100 0.3559
Stage 2 8-10 0.0467 0.2243 0.1648 0.2806 20-25 0.0467 0.4408 0.3266 0.5544
Global (80) 0.0499 0.3206 0.3039 0.3791 (200) 0.0483 0.6102 0.5896 0.7134
Non-weighting Stage 2 8-10 0.0450 0.2038 0.1428 0.2550 20-25 0.0422 0.3908 0.2679 0.4928
ADTARI Global (80) 0.0490 0.3089 0.2884 0.3643 (200) 0.0461 0.5888 0.5570 0.6844
One-Stage Global (80) 0.0424 0.3294 0.2262 0.4286 (200) 0.0418 0.6428 0.4484 0.7739
MCP-Mod
aI Stage 1 10 0.0397 0.1759 0.2130 0.1888 25 0.0369 0.3299 0.4120 0.3620
Stage 2 10 0.0455 0.2210 0.1520 0.2650 25 0.0420 0.4171 0.2668 0.5111
Global (80) 0.0503 0.3329 0.2999 0.3804 (200) 0.0484 0.6017 0.5614 0.6952
aII Stage 1 10 0.0381 0.1679 0.2103 0.1792 25 0.0368 0.3277 0.4093 0.3528
Stage 2 10 0.0390 0.2038 0.1012 0.2264 25 0.0366 0.3816 0.1547 0.4462
Global (80) 0.0440 0.3044 0.2470 0.3439 (200) 0.0426 0.5907 0.4626 0.6556
aIII Stage 1 10 0.0361 0.1704 0.2032 0.1842 25 0.0372 0.3241 0.4067 0.3551
Stage 2 10 0.0394 0.1716 0.2068 0.1781 25 0.0410 0.3289 0.4118 0.4075
Global (80) 0.0447 0.2747 0.3515 0.3043 (200) 0.0444 0.5472 0.6625 0.6238
aIV Stage 1 10 0.0345 0.1688 0.2145 0.1837 25 0.0390 0.3237 0.4213 0.3542
Stage 2 8 0.0439 0.2078 0.1503 0.2590 20 0.0437 0.4028 0.2702 0.4982
Global (80) 0.0501 0.3146 0.2992 0.3723 (200) 0.0466 0.5951 0.5675 0.6888
Table 5: PoAs of ADTARI, Non-weighting ADTARI, One-Stage MCP-Mod, and four two-
stage fixed designs under varying D-R shape × sample size (2)
Design Test n1i/gp Data-Generating Function n1i/gp Data-Generating Function
Choice Stage n2i/gp n2i/gp
(N) Const. Emax Quad. Logist. (N) Const. Emax Quad. Logist.
ADTARI Stage 1 50 0.0403 0.5411 0.6667 0.5979 75 0.0393 0.7054 0.8205 0.7601
Stage 2 40-50 0.0464 0.7327 0.5658 0.8261 60-75 0.0468 0.8865 0.7340 0.9434
Global (400) 0.0504 0.8747 0.8555 0.9369 (600) 0.0521 0.9674 0.9527 0.9893
Non-weighting Stage 2 40-50 0.0417 0.6487 0.4409 0.7587 60-75 0.0397 0.8008 0.5722 0.9005
ADTARI Global (400) 0.0478 0.8551 0.8261 0.9205 (600) 0.0473 0.9570 0.9382 0.9845
One-Stage Global (400) 0.0411 0.8879 0.7032 0.9618 (600) 0.0446 0.9716 0.8663 0.9949
MCP-Mod
aI Stage 1 50 0.0386 0.5378 0.6685 0.5878 75 0.0422 0.7053 0.8287 0.7508
Stage 2 50 0.0454 0.6569 0.4245 0.7817 75 0.0447 0.8177 0.5752 0.9117
Global (400) 0.0481 0.8645 0.8246 0.9259 (600) 0.0514 0.9601 0.9409 0.9844
aII Stage 1 50 0.0368 0.5422 0.6636 0.5837 75 0.0378 0.7117 0.8231 0.7670
Stage 2 50 0.0405 0.6306 0.2462 0.7159 75 0.0401 0.7863 0.3355 0.8582
Global (400) 0.0477 0.8493 0.7368 0.8999 (600) 0.0450 0.9498 0.8799 0.9772
aIII Stage 1 50 0.0396 0.5514 0.6693 0.5883 75 0.0370 0.7098 0.8297 0.7594
Stage 2 50 0.0379 0.5467 0.6664 0.5888 75 0.0351 0.7074 0.8322 0.7598
Global (400) 0.0446 0.8170 0.9070 0.8521 (600) 0.0405 0.9318 0.9793 0.9541
aIV Stage 1 50 0.0421 0.5469 0.6673 0.5853 75 0.0364 0.6961 0.8273 0.7561
Stage 2 40 0.0448 0.6448 0.4411 0.7750 60 0.0446 0.7991 0.5857 0.8977













































Total sample size (N)=200
Figure 3: Proof of Activity in Global Stage for Different Dose-Response Patterns in ADTARI,
Non-weighting ADTARI, One-Stage MCP-Mod, Maximum, and Minimum designs
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both stages are 300, then the aggregate sample sizes for the pre-specified candidate doses,
d0, . . . , d4, are computed as shown in Figure 4b. The resulting sample sizes are not balanced
across doses in 10, 000 trials (35% variation). This is because 1) ADTAR I (Section 2) does
not map the potential results, b1, . . . , b8, to the pre-specified adaptation choices, a1, . . . , a4,
in a one-to-one fashion and 2) the number of potential results in Stage 1 that map to the
adaptation choices is not the same across the adaptation choices. Furthermore, doses to
be used in Stage 2 are not the same across the four adaptation choices. Hence, adjusting
the aggregate sample sizes with our proposed weights (Table 3), the sample size imbalance
is much improved (≤ 5% variation) as shown in Figure 4c. This example illustrates how
a missing data mechanism in Stage 2 can result using an ADTAR approach and how our
weighting based on a missing data analysis can compensate the resulting imbalanceness.
3.4.4 Controlling the FWER
In this section, we evaluate how much a pre-specified ADTAR can control the FWER close
to a pre-chosen 0.05 level in a two-stage design (as discussed in Section 3.3). To do so, we
compare our ADTAR design with a random two-stage design without ADTAR. We simulated
10, 000 trials using a random two-stage design, denoted as Random Two-Stage, where all 15
dose combinations are equally possible choices in Stage 2 (Figure 5). Table 6 shows both
Stage 2’s and global PoA results for four different models (Emax, Logistic, Quadratic, and
Constant) and four different total sample sizes (N = 80, 200, 400, and 600). As shown for
the data generated by the constant model, Stage 2’s PoA results are as low as 0.031 across
different total sample sizes. As a result, the global PoA under the constant model also
seems to be lower than the ideal value of 0.05 for all sample sizes. As we can see in this
example, without specifying ADTAR in a two-stage design, the FWER can be over-controlled













Potential PoC results in Stage 1












































(c) Sample sizes with weighting
Figure 4: Equal probability of Stage 1’s results and sample sizes with and without weighting.
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Figure 5: Random Two-Stage design
Table 6: PoAs of Random Two-Stage design under varying D-R shape × sample size
Design Test n2i/gp Data-Generating Function n2i/gp Data-Generating Function
Choice Stage (N) Const. Emax Quad. Logist. (N) Const. Emax Quad. Logist.
Random Stage 2 8-20 0.0354 0.1874 0.1337 0.2012 20-50 0.0319 0.3688 0.2673 0.3970
Two-Stage Global (80) 0.0438 0.2975 0.2845 0.3098 (200) 0.0391 0.5705 0.5544 0.5937
Random Stage 2 40-100 0.0372 0.5896 0.4242 0.6060 60-150 0.0359 0.7377 0.5533 0.7090
Two-Stage Global (400) 0.0437 0.8347 0.8113 0.8318 (600) 0.0435 0.9295 0.9261 0.9145
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3.5 DISCUSSION
In this chapter, we presented an extension of the MCP-Mod method by Branson, et al. and
Bretz, et al. from a classical clinical trial design to an adaptive two-stage trial design. Among
a set of potential doses, several doses and a placebo were used in the first stage. In the
second stage, doses were selected (including the placebo) according to our pre-specified dose
adaptation rule called ADTAR. In both stages, we used the same set of the dose-response
candidate models. Each stage used the model-associated multiple contrast test statistics for
the preliminary hypothesis testing on dose-response relationship. We then combined the test
results of both stages in order to establish global PoC via a conditional error function.
We focused on one of the three objectives in the original MCP-Mod method; our research
goal was to establish global PoC after adaptively adding and/or dropping treatment doses
in the second stage based on the result of the first stage. For the second stage, we showed
how to model potentially unequal sample sizes and dropped doses across adaptation choices
due to ADTAR function using the missing data weighting method.
In the simulation studies, we evaluated the performance of our proposed ADTAR ap-
proach for detecting a dose-response curve called Proof of Activity (PoA). The ADTAR
approach roughly preserved the FWER at a 5% level. The missing data weighting method
in Stage 2 improved PoA within the same ADTAR design. Furthermore, the ADTAR ap-
proach showed more a robust performance across the three forms of the true dose-response
curves in establishing global PoC compared to the conventional study designs. In particular,
for the quadratic dose-response, the ADTAR approach was superior in PoA to the one-stage
design of the original MCP-Mod method. Additionally, the ADTAR approach showed ade-
quate power compared to the maximum and minimum power from the four fixed two-stage
designs.
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4.0 CONSTRAINTS OF DOSE CHOICES IN THE MULTIPLE
COMPARISON PROCEDURES AND MODELING APPROACH
In this chapter, we describe constraints for choosing doses in using the MCP-Mod and
our extended MCP-Mod (Ex-MCP-Mod) methods. We identify the constraints which are
imposed by both the estimation form of correlation matrix in an adaptive two-stage design
and floating-point arithmetic. We discuss the relationship of these constraints and ADTAR
in the Ex-MCP-Mod method as well.
4.1 CONSTRAINTS TO DOSE CHOICES IN THE MCP-MOD
To implement the MCP-Mod method or Ex-MCP-Mod method in Sections 2.4 and 3.1,
respectively, several pre-specifications are required in the design protocol. A set of dose
choices is one such pre-specification. In our previous research, we noted that a set of potential
levels of doses in the MCP-Mod method and Ex-MCP-Mod method were constrained. In
this section, we further discuss the constraint in choosing a set of doses for the MCP-Mod
method.
As seen in Section 2.4, it is assumed that the vector of M model-associated contrast
statistics as in (2.4) of the MCP-Mod method follows a M -variate t-distribution under the
null hypothesis. To hold this assumption, its numerically computed correlation matrix,
R = (ρuv), 1 ≤ u, v ≤ M , must be positive definite. Since the matrix elements, ρuv, are
functions of doses, a set of doses must be chosen to satisfy this requirement.
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For simplicity, we consider equal sample sizes for the placebo group and k dose groups













||cu||||cv|| , 1 ≤ u, v ≤M. (4.1)
Remember that the optimal contrast vectors, cm, m = 1, . . . ,M , satisfy the regulatory
conditions and maximize the non-centrality parameter of the multivariate t-distribution.
Let µ0m = (µ
0
m0, . . . , µ
0
mk)
′ be the standardized mean vector obtained from the standardized
model, f 0m, with doses d0, . . . , dk, and let µ
0
m be the average of the k+ 1 mean values. Then,
each optimal contrast vector is expressed with µ0m and µ
0




, m = 1, . . . ,M. (4.2)
To illustrate, let us focus on the three standardized models: Emax (f 01 ), quadratic (f
0
2 ),
and logistic (f 03 ) models as shown in Table 1 and Figure 4 in Section 3.4. These models were
used in both the MCP-Mod (Bretz, et al., 2005) and Ex-MCP-Mod methods. Again, given
a set of candidate dose-response models, dose specification determines the correlations and
the model contrast vectors as in (4.1) and (4.2), respectively. Therefore, one can expand the
following discussion to the other models of Bretz, et al. [6].












Since symmetric R3× 3 must be positive definite, we obtain the following necessary and
sufficient conditions from Sylvester’s criterion [17].
1. The upper 1× 1 matrix has a positive determinant.
2. The upper 2× 2 matrix has a positive determinant, i.e., 1− ρ212 > 0.
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3. The 3× 3 matrix has a positive determinant, i.e., 1 + 2ρ12ρ23ρ13 − (ρ212 + ρ223 + ρ213) > 0.
Note that the first condition is always met in the computed matrix. The third condition
is the main component of the constraint for dose specification in the MCP-Mod method.
These three conditions together signify that the correlation elements must be within the







( ρ23 ρ13 ) = 1, (4.4)
where −1 < ρ12, ρ23, ρ13 < 1. Let (ρ23, ρ13, ρ12) be a point in the XY Z coordinate system.
Performing a coordinate transformation using X = U+V√
2
and Y = −U+V√
2
, we illustrate the
three-dimensional shape as Figure 6a. The shape seems similar to a tetrahedron having
vertices at (1, −1, −1), (−1, 1, −1), (−1, −1, 1), and (1, 1, 1) in the XY Z-coordinate.





1−c = 1 (see Figure 6c and 6d). Especially at Z = 0, the surface is circular defined as
X2 + Y 2 = 1 (Figure 6b). The three-dimensional object within the boundary described by







i.e., it is greater than half of the circumscribing cube. Accordingly, we expect that many
dose combinations will allow the computed correlation matrix, R3× 3, to be numerically
positive definite.
In the Ex-MCP-Mod method, recall that we use weighted contrast test statistics in the
second stage of a two-stage adaptive design. Using such weights, the correlation matrix is
also weighted. Suppose that an ADTAR function defines L adaptation choices in the second
stage. Let ωij denote the weight which is used to adjust the mean estimate of dose group i
for a contrast test statistic given adaptation choice aj ∈ {a1, . . . , aL}. The weight formula is
derived based on the ADTAR function and
∑L
j=1 ωij = 1 (see Section 3.2). Assuming equal
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sample sizes within the selected adaptation which uses the placebo and k2 dose groups, the

















, 1 ≤ u, v ≤M. (4.5)
If we use the same set of the candidate dose-response models in Table 1, then the weighted
correlation matrix of the second stage is R2 3× 3 = (ρuv)2, 1 ≤ u, v ≤ 3. To construct
the valid Ex-MCP-Mod method, R2 3× 3 must also be numerically positive definite. For
this reason, in the next section, our simulation study investigates positive definiteness of
both un-weighted and weighted matrices for the MCP-Mod method and the Ex-MCP-Mod
method, respectively.
4.2 SIMULATION STUDY
In this section, we show how numerical positive definiteness of a computed correlation matrix
depends on dose choices in the MCP-Mod method via a simulation study. We investigate
appropriate dose combinations by level plots on the smallest eigenvalues and which dose
combinations allow for a computed correlation matrix to be numerically positive definite.
For the Ex-MCP-Mod method, we investigate the effect of adaptive weighting of ADTARs
on the positive definiteness of the un-weighted matrix.
4.2.1 Simulation Method
The MCP-Mod method and Ex-MCP-Mod method require pre-specifications on both dose
levels and candidate dose-response models in a design protocol. In our simulation study, we
assume the same specification of Section 4.1 with respect to candidate dose-response models
as f1, f2, and f3 (Table 1 and Figure 4) in the MCP-Mod/Ex-MCP-Mod methods. Given
such model specifications, we search for the appropriate number of doses and the appropriate
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(a) 3D-Shape (b) 3D-Shape cut at Z = 0
(c) 3D-Shape cut at Z = 0.7 (d) 3D-Shape cut at Z = −0.7
Figure 6: Three-Dimensional Shape of Correlation Elements.
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levels of doses from the dose range, [0, 1.0]. The dose range was chosen to be able to cover
both the dose of the minimum response effect and the dose of the maximum response effect
on each standardized dose-response model. The simulation study was implemented using
the R package (Version 2.10.1). The R programs for implementing the simulation study
are available in Appendix A.4. Since the R system is implemented using IEEE double
standard precision numbers [23], results of computations between −10−16 and 10−16 cannot
distinguished from 0. Therefore, we consider any numbers in this interval to be 0 when
establishing positive definiteness of evaluate values.
4.2.2 Optimal Number of Doses
First, to find the appropriate number of doses, we simulate all possible dose combinations
from dose range [0, 1.0] using a placebo group (d0 = 0) and the respective two dose groups
(k = 2: d1 and d2), three dose groups (k = 3: d1, d2 and d3), and four dose groups (k = 4:
d1, d2, d3 and d4). An equal interval size between doses is fixed as 0.20, 0.10, 0.07, or 0.05.
The associated numbers of potential dose choices within the dose range are 5, 10, 15, and
20, respectively. The smallest eigenvalues of the correlation matrices are computed for all
dose combinations based on (4.1) and (4.2).
Employing equivalent conditions for positive definiteness of a matrix, a correlation matrix
is positive definite if all eigenvalues are positive real numbers [26]. The correlation matrix in
(4.3) is symmetric, and we know that all eigenvalues of a symmetric matrix are real numbers.
Therefore, to establish positive definiteness of a correlation matrix, it is sufficient to prove
that the smallest eigenvalue is positive. For each set of doses, we evaluate numerical positive
definiteness of computed matrices by computing the minimum and maximum of the smallest
eigenvalues of the correlation matrices. If a range of the smallest eigenvalues covers positive
real values, the corresponding number of doses is an appropriate candidate as the number
of doses in the MCP-Mod method.
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Table 7: The Minimum and Maximum of The Smallest Eivgenvalues of The Correlation
Matrices For Different Number of Doses Simulated From Equal Dose Intervals in [0,1]
number of potential
a set of doses doses in [0,1] 5 10 15 20
d0, d1 (k = 1) minimum −2.44× 10−17 −9.74× 10−17 −9.74× 10−17 −9.74× 10−17
maximum 1.37× 10−16 1.59× 10−16 3.59× 10−16 1.59× 10−16
d0, d1, d2 (k = 2) minimum −1.12× 10−16 −4.88× 10−16 −5.35× 10−16 −5.86× 10−16
maximum 1.59× 10−16 5.01× 10−16 5.19× 10−16 5.57× 10−16
d0, d1, d2, d3 (k = 3) minimum 2.30× 10−3 6.94× 10−5 1.06× 10−5 2.97× 10−6
maximum 0.0104 0.0150 0.0159 0.0159
d0, d1, d2, d3, d4 (k = 4) minimum 0.0125 4.42× 10−4 6.57× 10−5 1.80× 10−5
maximum 0.0125 0.0163 0.0176 0.0179
Note: The sample size, ni = 20, was used for each group. Minimum and maximum refer to the smallest eigenvalues.
Table 7 shows the computed ranges of the smallest eigenvalues for different numbers
of treatment doses, k = 1, 2, 3, and 4, and different numbers of potential dose choices in
[0, 1.0]. In this table, when the number of treatment doses is k = 1 or k = 2, the computed
correlation matrices are not numerically positive definite. When the number of treatment
doses is k = 3 or k = 4, the computed correlation matrices are numerically positive definite.
Figures 7 and 8 show the range determined by the minimum and maximum log 10 of the
smallest eigenvalues of the computed correlation matrix for k = 3 and k = 4, respectively.
From the result, we see that at least more than two treatment groups need to be specified
in the MCP-Mod method. As a necessary condition, the same condition must hold if one
plans to use the Ex-MCP-Mod employing an ADTAR in an adaptive two-stage design.
4.2.3 Optimal Levels of Doses
Next, to find appropriate levels of doses, we simulate sets of the placebo group (d0 = 0) and
the respective number of dose groups (k = 1, 2, 3 and 4) in increasing order of doses, from
d1 to d4, using various equal intervals: 10
−1, 10−2, . . . , 10−10. For example, we evaluate doses
(0, 0.01, 0.02, 0.03) for 10−2 intervals with k = 3. For each set of doses, we evaluate numer-
ical positive definiteness of the computed correlation matrices by computing the minimum
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Figure 7: The Minimum and Maximum Log 10 of the Smallest Eigenvalues of R3× 3 for a
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Figure 8: The Minimum and Maximum Log 10 of the Smallest Eigenvalues of R3× 3 for a
Placebo and Four Treatment Doses (d1, d2, d3, and d4).
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Table 8: The Minimum of The Smallest Eivgenvalues of The Correlation Matrices Against
Various Dose Intervals For Different Number of Doses
equal dose intervals 10−1 10−2 10−3 10−4 10−5
(a set of doses)
d0, d1 8.65× 10−17 −2.44× 10−17 −9.32× 10−18 1.59× 10−16 1.37× 10−16
d0, d1, d2 2.32× 10−16 1.14× 10−16 −1.70× 10−16 1.45× 10−16 −1.44× 10−16
d0, d1, d2, d3 8.41× 10−5 2.07× 10−8 2.35× 10−12 4.72× 10−16 3.76× 10−16
d0, d1, d2, d3, d4 3.06× 10−4 7.93× 10−8 9.35× 10−12 1.11× 10−15 5.24× 10−17
equal dose intervals 10−6 10−7 10−8 10−9 10−10
(a set of doses)
d0, d1 1.59× 10−16 8.65× 10−17 1.25× 10−16 −2.44× 10−17 4.57× 10−17
d0, d1, d2 −9.15× 10−17 3.17× 10−16 8.65× 10−17 −3.48× 10−16 3.95× 10−16
d0, d1, d2, d3 −1.41× 10−16 5.43× 10−18 8.65× 10−17 −1.12× 10−16 −2.68× 10−16
d0, d1, d2, d3, d4 1.08× 10−16 3.34× 10−16 −2.69× 10−16 5.19× 10−16 2.12× 10−16
Table 8 shows the computed minimum values of the smallest eigenvalues. Figure 9 shows
the log 10 plots of the computed minimum values of the smallest eigenvalues. In this figure,
when the number of dose groups is k = 1 or k = 2, the computed correlation matrices are
not numerically positive definite for any of the evaluated dose intervals. When the number
of dose groups is k = 3 or k = 4, the computed correlation matrices are numerically positive
definite. However, they numerically approach the indefinite as the dose interval gets smaller.
From this result, the equal interval between doses needs to be greater than or equal to 10−3
for k ≥ 3 in the MCP-Mod method as it requires a numerically positive definite correlation
matrix. In our situation, for two doses and placebo, the MCP-Mod can never be used.
4.2.4 The Best Configurations of Doses
To show the best configurations of levels of doses in the MCP-Mod method, we simulate all
possible sets of the placebo and three dose groups (as ordered from d1 to d3) with an equal
dose interval, 0.05, in the range of [0, 1.0]. The relevant number of potential doses in [0, 1.0]
is 20. For each fixed value of the largest dose group, d3, we create a level plot of the smallest
eigenvalues associated with all possible combinations of the first and second dose groups,
d1 and d2. In such a level plot, the best configurations of dose levels can be presented by



































Equal dose intervals [log10]
Figure 9: Log 10 of The Smallest Eigenvalues of R3× 3 for Varying Dose Intervals in [0, 1.0].
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Figures 10 and 11 show the log 10 level plots of the smallest eigenvalues for all
possible dose combinations between d1 and d2 at the descending fixed values of d3:
1.00, 0.95, 0.90, . . . , 0.15. For example, in Figure 10-(a) (d1, d2)=(0.20, 0.65) is one
of the best configurations between the rest of the two dose groups with d3 = 1.00. Overall,
the best configurations seem to be established when dose intervals are relatively large and
when levels of doses are spread out enough over the range of [0, 1.0].
4.2.5 The Weighting Effect on Positive Definiteness
As a result of Sections 4.2.2 and 4.2.3, if the number of treatment groups is greater than or
equal to three and if equal dose intervals are greater than or equal to 10−3, the computed cor-
relation matrix in the MCP-Mod is numerically positive definite. Accordingly, these are the
necessary conditions for holding the Ex-MCP-Mod method. In order to numerically investi-
gate if the two conditions are also sufficient for the Ex-MCP-Mod method, i.e., if weighting
in the second stage of the Ex-MCP-Mod does not change the numerical positive definiteness
of the computed un-weighted matrix, we simulate all possible ADTAR functions where the
number of treatment groups in the second stage (k2) is either three or four (k2 ≥ 3) out of
four potential doses. Equal dose intervals are set to be 0.20, 0.10, or 0.05. The associated
numbers of potential dose choices within the dose range are 5, 10, and 20, respectively. Then,
we compute the weighted matrices in (4.5) and the minimum of the smallest eigenvalues from
all the ADTARs for each set of doses. In the respect cases of k2 ∈ {3, 4} and k2 ∈ {2, 3, 4},
if the lower bound of the minimum eigenvalues is positive for all the simulated sets of doses,
then the corresponding k2 is considered to be one sufficient condition to construct a valid
ADTAR in the Ex-MCP-Mod method. Our extensive simulation showed that the lower
bound of the minimum eigenvalues was greater than 0 (> 10−6) for simulating k2 ∈ {3, 4}
but not numerically positive (< 10−15) for simulating k2 ∈ {2, 3, 4}. Consequently, in an
ADTAR function at least three treatment groups must be used in each adaptation choice.
This simulation result does not provide any additional condition to the necessary conditions
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(a) d3 = 1.00 (b) d3 = 0.95 (c) d3 = 0.90
(d) d3 = 0.85 (e) d3 = 0.80 (f) d3 = 0.75
(g) d3 = 0.70 (h) d3 = 0.65 (i) d3 = 0.60
Figure 10: Log 10 of the Smallest Eigenvalues of R3× 3 for a Placebo and Three Treatment
Doses (d1, d2, and d3).
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(a) d3 = 0.55 (b) d3 = 0.50 (c) d3 = 0.45
(d) d3 = 0.40 (e) d3 = 0.35 (f) d3 = 0.30
(g) d3 = 0.25 (h) d3 = 0.20 (i) d3 = 0.15
Figure 11: Log 10 of the Smallest Eigenvalues of R3× 3 for a Placebo and Three Treatment
Doses (d1, d2, and d3).
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in the Ex-MCP-Mod method. Therefore, we conclude that weighting based on an ADTAR
function does not change the numerical positive definiteness of the computed un-weighted
matrix. The necessary and sufficient conditions for the MCP-Mod method remain the same
for the Ex-MCP-Mod method.
4.3 DISCUSSION
Our analysis and experiments showed that given the three candidate dose-response models,
the Emax, quadratic, and logistic models, the MCP-Mod method is stable if the number of
treatment groups does not fall below three and if equal dose intervals are greater than or
equal to 10−3 in dose range [0, 1.0]. In the Ex-MCP-Mod method, ADTAR functions and
derived weights do not affect numerical positive definiteness of the computed un-weighted
correlation matrices; the Ex-MCP-Mod method using an ADTAR function is valid if the
same conditions as above hold. When formulating an ADTAR function, it seems to be an
unavoidable constraint that at least three treatment groups must be used in the second stage
of a two-stage design. However, from the practical stand point, this constraint would not be
so critical, because according to the second condition the levels of doses are allowed to be
relatively close. Thus, one can pre-specify flexible adaptations using an ADTAR function
without selecting dosage levels that are too high and toxic for the second stage.
If in the simulation study, Emax, quadratic, and logistic models are pre-specified as the
candidate dose-response models in the MCP-Mod, it is preferable to distribute potential
doses evenly between placebo and the highest dose chosen for the trial. Our algorithm to
search for appropriate dose candidates is applicable to other candidate dose-response models
for the MCP-Mod/Ex-MCP-Mod methods. Level plots are especially useful to visualize the
appropriate dose combinations. Our findings and proposed algorithm should aid the design
of a dose-response study when one wishes to employ the MCP-Mod/Ex-MCP-Mod methods.
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5.0 CONCLUSION
In this dissertation, we proposed to generalize one previously developed method for two-stage
adaptive designs to accommodate situations where both adding and dropping treatment arms
are possible between stages. Our procedure was based on using the data set in its entirety
and would control for the familywise error rates. Specifically, we proposed
1. to develop an efficient two-stage study design where an adaptation rule adding and/or
dropping treatment arms, which we call ADTAR, is pre-specified;
2. to use our adaptive design to establish evidence of a global dose-response relationship or
Proof of Concept (PoC) for a treatment; and
3. to show that the two-stage design with the pre-specified adaptation rule can be used to
improve statistical power in establishing global PoC.
In Chapter 3, we introduced a pre-specified adaptation rule that adds and/or drops
treatment arms between stages, and we called this rule ADTAR. We aimed to follow the
FDA’s draft guidance on adaptive designs, which advises that clinical experimenters detail
adaptation rules in protocols as much as possible. For establishing PoC in drug development,
we showed that using an ADTAR function in adaptive two-stage designs adds flexibility
over conventional designs and fixed two-stage designs. In addition, the pre-specification of
adaptation rules allowed us to increase power and prevents over-controlling the FWER by
limiting the adaptation choices compared to two-stage designs without pre-specified rules. In
our simulation studies, we showed that redistributing the sample sizes of the unused arms to
the retained arms in Stage 2 could allow the ADTAR approach to preserve and potentially
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increase power in detecting evidence of dose-response from fixed two-stage designs of the
same total sample sizes.
In Chapter 4, practical considerations for dose pre-specification for Bretz et al.’s MCP-
Mod method and our Ex-MCP-Mod method were described. In particular, we established
lower bounds for the number and levels of doses for each method in a simulation study.
These constraints were imposed by both the formula of the correlation matrix and floating-
point arithmetic. We showed that as long as the computed un-weighted correlation matrices
were numerically positive definite, the Ex-MCP-Mod method did not impose any further
constraints on the adaptive two-stage design with the same dose pre-specification. Our
findings and proposed algorithm should aid the design of a dose-response study when one
wishes to employ the MCP-Mod/Ex-MCP-Mod methods.
In summary, we developed a novel type of pre-specified adaptation rule, ADTAR, for
use in adaptive two-stage designs in order to comply with the recommendation in the FDA’s
draft guidance. Using simulation studies, we showed that
1. the FWER is controlled in establishing global PoC in our design;
2. in our design, statistical power for PoC tests is robust and potentially superior to con-
ventional and fixed two-stage designs; and
3. there are constraints for pre-specifying the number and levels of doses in clinical trials
when we use the MCP-Mod method. Our Ex-MCP-Mod method does not impose further
constraints over the original MCP-Mod method.
The results of this thesis suggest further investigation of 1) identifying the best candidate
dose-response model, and 2) determining a target treatment dose in the proposed design
method. Due to logistic considerations in drug development, effective sample allocation and
the relationship between sample allocation and PoA are also topics for further investigation.
Finally, one open question remains about how to find the optimal ADTAR, which depends




R PROGRAMS FOR SIMULATION STUDIES
A.1 PROOF OF ACTIVITY (POA) OF ADTAR I (CHAPTER 3)
library(mvtnorm)
##########################################################################
### Note: This program performs Establishment of PoC.
### Equal sample size per dose group in Stage 1 is set to be 75.
### This number must be replaced to 10, 25, or 50 for the other simulations.
### Equal sample sizes in Stage 2 must be replaced accordingly.
### All PoC tests are one-sided.
### Used a critical value from MVT for individual tests.
### Non-weighting in Stage 2 is also evaluated.
### Function to get rid of NAs from a matrix for Stage 2.
fun = function(MATRIX) {
LOG = is.na(MATRIX)








for (i in 1:P) {




for (j in 1:Q) {








### Function to get rid of all-zero rows.
fun2 = function(MATRIX) {
P = nrow(MATRIX);
NA.row = rep(NA,P);
for (i in 1:P) {




if(length(na.exclude(NA.row)) >= 1) {







### Function to compute a component of weight matrix.





# I. planning a trial #
############################
# Number of simulated trials.
L <-100
# number of the candidate D-R models.
m<-3
# number of adaptation choices in Stage 2.
adpt.L<-4
# (adpt.L choices x k+1 doses) design matrix for dose adaptation in Stage 2.
Z<-matrix(c(1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1),nrow=adpt.L)
tZ<-t(Z)
# Matrix for associating PoC results in Stage 1 with adaptations in Stage 2.
J<-matrix(c(1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1),ncol=m)
# g function: g* is adaptation number out of adpt.L choices.




if (z <= 2){
adpt.a[1]=2
}
if (z == 4|z == 6){
adpt.a[2]=2
}
if (z == 7){
adpt.a[3]=1
}














### Model Specification, Standardizing Models, and Empty Matrices for Evaluation ###
## 1. Obtain optimal regression coefficients (c_opt). ##
# maximize the power of the test == non-centrality parameter with regulatory condition.
# Using ragranges, we solve the formula and obtain c_opt vector.
# Maximum effect size.
delta.max<-0.6
# Dose to produce the half of the maximum effect.
ED50<-0.2
alpha<-0.025
compute_emax_c1_opt_m1 = function(kandP, n_stg, doses_stg) {
# Identity matrix of the number of dose size.
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
# Identity matrix of the number of patients/group size.
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### I. Standardized Emax Model.

























compute_quad_c1_opt_m2 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### II. Standardized quadratic Model.

























compute_logis_c1_opt_m3 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### III. Standardized Logistic Model.
























compute_cr1 = function(doses_stg, samples){








## 2. Find the critical value for PoC test H0 ###
# Refer to ’UsingMvtPackage.pdf’.
# The decision rule: use the best contrasts for computing the test statistic (Tmax).
61
# compute the critical value for the H0 test.
# Note: the linear contrast matrix under H0 is C1.
V1<-diag(1/n_stg1)
df1<-N1-k1andP








compute_cr2 = function(doses_stg, samples, W_a){









































### Stage 2 setting ###


























# Compute Critical Values for Global PoC test.#
chi_df4_p975L<-qchisq(p=0.975, df=4, ncp=0, lower.tail = TRUE, log.p = FALSE)
GH_Mi_critValp975L<-exp(-(chi_df4_p975L)/2)
### A. Constant Data-Generating Function ############################################
#####################################
# II. Stage 1: Data Generating #
#####################################
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### Prepare the empty matrices to fill the results for evaluation (see #IV#) ###
# for Stage 1
ps_stg1 = array(c(0),dim=c(4,L))
# for Stage 2
ps_stg2 = array(c(0,0,0,0),dim=c(4,L))
# column 1: M1 p-value for H(s,1) using a univ. T-dist,
# column 2: M2 p-value for H(s,2) using a univ. T-dist,
# column 3: M3 p-value for H(s,3) using a univ. T-dist,
# column 4: mvt.prob1.
# Note: s=1, 2 (stage).
ps_stg2.noWt = array(c(0,0,0,0),dim=c(4,L))




# for Stage 2: for model 1, model 2, and model 3.
m.s2 = array(c(0,0,0),dim=c(3,L))
PoC_Gps = array(c(0,0,0,0),dim=c(4,L)) # for Global Tests.
# column 1: product of two (pVal from MVT).
PoC_Gps.noWt = array(c(0,0,0,0),dim=c(4,L)) # for Global Tests.
# Results of L trials for Stage 1 and adaptive treatment decision "a" or "g".
H0_result1<-matrix(rep(0,L*3),ncol=3)
# Results of L trials for Stage 2,the number of models in Stage 2.
H0_result2<-matrix(rep(0,L*1),ncol=1)
H0_result2.noWt<-matrix(rep(0,L*1),ncol=1)
# Results of L trials for Global Tests.
H0_resultG<-matrix(rep(0,L*6),ncol=6)
# column 1: overall global test based on MVT.
# column 2: global test on M1.
# column 3: global test on M2.
# column 4: global test on M3.
# column 5: Model # of the best model (the most significant model among M1,2,and 3).
# column 6: 1 if the best Model is significant.
H0_resultG.noWt<-matrix(rep(0,L*6),ncol=6)
### Dataset ’trial’ ###
# 1. Empty vectors& columns for dataset and specification.
# stage 1 #
simul.time<-
system.time(for(l in 1:L){
# Empty data matrix to fill samples using the data generating function.
mydata1<-matrix(0,nrow=n_stg1[1],ncol=k1andP)
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# Fill 1 if PoC is rejected for the model with the smallest p-value in the lth trial.
# To fill mean value mu0 of response Y for each dose group.
mu0<-c(rep(0,k1andP))
# To fill std.dv value sd0 of response Y for each dose group.
sd0<-c(rep(0,k1andP))
## 3. Draw sample size of nj for dose group j in the lth trial.##
for(j in 1:k1andP){
# std.dv of Y for dose j group are equally sd0=1.478.
sd0[j]<-1.478

















# III. Stage 1: Run the MCP-Mod #
#####################################
# analyzing a trial
# stage 1 #
## 4. Obtain the test stat w/ the best contrasts (c1_opt_m) ’Tmax_m’##
# Test statistic function. #
T1<-function(c){t(c)%*%mymean1/(s1*sqrt(t(c)%*%(solve(diag(n_stg1)))%*%c))}
# Test statistic T_m vector.#
T_m_stg1<-matrix(rep(0,m),nrow=1)
for(j in 1:m){













# IV. Evaluation of the MCP-Mod at every trial in Stage 1 #
############################################################
## 5. Test H0: the dose-response curve is flat ###
### Overall PoC test using MVT of m models in Stage 1.
### Note: this is using the critical value q_stg1.





### Individual models are tested based on a univariate t-distribution.
p_M1_stg1<-pt(T_M1_stg1, df1, lower.tail = FALSE, log.p = FALSE)
p_M2_stg1<-pt(T_M2_stg1, df1, lower.tail = FALSE, log.p = FALSE)
p_M3_stg1<-pt(T_M3_stg1, df1, lower.tail = FALSE, log.p = FALSE)
ps_stg1[,l]= c(p_M1_stg1,p_M2_stg1,p_M3_stg1,mvt.prob1)
Ts_stg1[,l] = c(T_m_stg1,T_max1) # T-stats for model 1, model 2, model 3 and Tmax.
#####################################
# V. Use ADTAR~I between Stages #
#####################################
# Check the result of Stage 1 to decide doses in Stage 2 based on ADTAR~I.
### ’a1’ uses the result of individual D-R testings.




if((T_M1_stg1 > q_stg1)&(T_M2_stg1 > q_stg1)&(T_M3_stg1 <= q_stg1)){
a1=2
g=1}

























# The result of Stage 1 into H0_result1 matrix.
H0_result1[l,2]=a1
H0_result1[l,3]=g
if (a1 <= 2){
doses_stg2=doses_stg2_g1
}
if (a1 == 4|a1 == 6){
doses_stg2=doses_stg2_g2
}
if (a1 == 7){
doses_stg2=doses_stg2_g3
}
if (a1 == 3|a1 == 5|a1 == 8){
doses_stg2=doses_stg2_g4
}
if (a1 <= 2){
n_stg2=n_stg2_g1
}
if (a1 == 4|a1 == 6){
n_stg2=n_stg2_g2
}
if (a1 == 7){
n_stg2=n_stg2_g3
}




k2andP=length(doses_stg2) # k + 1 in Stage 2 (# of treatment doses and the placebo).
#########################################################





# Weight the optimal contrast vector in Stage 2(plM_stg2$contMat).
if (a1 <= 2){
W_a=W_g1
}
if (a1 == 4|a1 == 6){
W_a=W_g2
}
if (a1 == 7){
W_a=W_g3
}
if (a1 == 3|a1 == 5|a1 == 8){
W_a=W_g4
}
#element-by-element operations on the weight and contrast vectors.
df2<-N2-k2andP
cr2<-compute_cr2(doses_stg2, n_stg2[1], W_a)











# get rid of NA values from cr2.
cr2.sub<-fun(cr2)




# 3. Fill the data from a data-generating function in Stage 2.
for(j in 1:k2andP){
#for(l in 1:n_stg2[j]){



















# VII. Stage 2: Run the Extended MCP-Mod #
##############################################
# analyzing a trial
# stage 2 #
## 4. Obtain the test stat w/ the best contrasts (c2_opt_m) ’Tmax_m’##
# Test statistic function. #
T2<-function(c){t(c)%*%mymean2/(s2*sqrt(t(c)%*%(solve(diag(n_stg2)))%*%c))}


































# VIII. Evaluation of the MCP-Mod at every trial in Stage 2 #
##############################################################
## 5. Test H0: the dose-response curve is flat ###
### Overall PoC test using MVT of m models in Stage 2.
### Note: this is using the critical value q_stg2.
delta.s2<-rep(0,length(subT.s2))





### Individual models are tested based on a univariate t-distribution.
p_M1_stg2<-pt(T_M1_stg2, df2, lower.tail = FALSE, log.p = FALSE)
p_M2_stg2<-pt(T_M2_stg2, df2, lower.tail = FALSE, log.p = FALSE)
p_M3_stg2<-pt(T_M3_stg2, df2, lower.tail = FALSE, log.p = FALSE)
ps_stg2[,l]= c(p_M1_stg2,p_M2_stg2,p_M3_stg2,mvt.prob2)
Ts_stg2[,l] = c(T_m_stg2,T_max2)
### Non weighted results using the critical value q_stg2.
delta.s2.noWt<-rep(0,length(subT.s2.noWt))







### Individual models are tested based on a univariate t-distribution.
p_M1_stg2.noWt<-pt(T_M1_stg2.noWt, df2, lower.tail = FALSE, log.p = FALSE)
p_M2_stg2.noWt<-pt(T_M2_stg2.noWt, df2, lower.tail = FALSE, log.p = FALSE)




# IX. Evaluation of the MCP-Mod at every trial #
#################################################
# 1. Evaluate PoC establishment (PoA evaluation)
## Global Tests ##
# -> Here I used the decision rule by the CEF.










## Global Tests without Weights ##





























} # This is the end of i loop (see #1#).
)
##########################################
# X. Evaluation summary of L trials. #
##########################################
### MCP-Mod Hypothesis: no-response curve.
### =>If rejected, at least one of (M1, M2 M3) is significant.
### MVT based ###
## Stage 1 ##
PoA_stg1_MCPMod.MVT<-mean(H0_result1[,1])
PoA_stg1_MCPMod.MVT
## Stage 2 ##
PoA_stg2_ExMCPMod.MVT<-mean(H0_result2[,1])
PoA_stg2_ExMCPMod.MVT
## Global Test by Fisher’s Combination Test ##
PoA_Global_ExMCPMod.MVT<-mean(H0_resultG[,1])
PoA_Global_ExMCPMod.MVT
## Stage 2 without Weights ##
PoA_stg2_ExMCPMod.MVT.noWt<-mean(H0_result2.noWt[,1])
PoA_stg2_ExMCPMod.MVT.noWt
## Global Test by Fisher’s Combination Test ##
PoA_Global_ExMCPMod.MVT.noWt<-mean(H0_resultG.noWt[,1])
PoA_Global_ExMCPMod.MVT.noWt









Note: From here, we only show the different data-generation code. The rest of this program
is omitted as the same coding is used for the other Emax, quadratic, and logistic data.
### B. Emax Data-Generating Function ############################################
### Dataset ’trial’ ###
# stage 1 #
for(j in 1:k1andP){
sd0[j]<-1.478




### Dataset ’trial’ ###






### C. Quadratic Data-Generating Function ############################################
### Dataset ’trial’ ###
# stage 1 #
for(j in 1:k1andP){
sd0[j]<-1.478




### Dataset ’trial’ ###






### D. Logistic Data-Generating Function ############################################
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### Dataset ’trial’ ###
# stage 1 #
for(j in 1:k1andP){
sd0[j]<-1.478




### Dataset ’trial’ ###










### Note: This program performs Establishment of PoC.
### The total sample size of the one-stage design is set to be 80 (16 x 5 groups).
### This number must be replaced to 200, 400, or 600 for the other simulations.
############################




### Stage 1 setting ###
n0_stg1 <- 16 # Input sample size for Placebo
n1_stg1 <- 16 # Input sample size for Treatment 1 (d=0.05)
n2_stg1 <- 16 # Input sample size for treatment 2 (d=0.2)
n3_stg1 <- 16 # Input sample size for treatment 3 (d=0.6)





# k + 1 in Stage 1 (# of treatment doses and the placebo).
k1andP=length(doses_stg1)
### Model Specification, Standardizing Models ###






### I. Standardized Emax Model.

















### II. Standardized quadratic Model.















### III. Standardized Logistic Model.


























# Compute Critical Values for Global PoC test.#
# critical value at lower 975%tile. #
chi_df4_p975L<-qchisq(p=0.975, df=4, ncp=0, lower.tail = TRUE, log.p = FALSE)
GH_Mi_critValp975L<-exp(-(chi_df4_p975L)/2)
### A. Constant Data-Generating Function ############################################
#####################################
# II. Stage 1: Data Generating #
#####################################





### Dataset ’trial’ ###
# 1. Empty vectors&columns for dataset and specification.
























# III. Stage 1: Run the MCP-Mod #
#####################################
# analyzing a trial
# stage 1 #
## 4. Obtain the test stat w/ the best contrasts (c1_opt_m) ’Tmax_m’##
# Test statistic function. #
T1<-function(c){t(c)%*%mymean1/(s1*sqrt(t(c)%*%(solve(diag(n_stg1)))%*%c))}














# IV. Evaluation of the MCP-Mod at every trial in Stage 1 #
############################################################
## 5. Test H0: the dose-response curve is flat ###
### Overall PoC test using MVT of m models in Stage 1.
mvt.prob1 <- pmvt(lower=T_m_stg1, delta=delta, df=df1, corr=cr1)
attributes(mvt.prob1)<-NULL
if(mvt.prob1 < 0.025){H0_result1[l,4]=1}
### Individual models are tested based on a univariate t-distribution.
p_M1_stg1<-pt(T_M1_stg1, df1, lower.tail = FALSE, log.p = FALSE)
p_M2_stg1<-pt(T_M2_stg1, df1, lower.tail = FALSE, log.p = FALSE)




# V. Check the interim result between Stages #
#################################################
# Check the result of Stage 1 to decide doses in Stage 2 based on ADTAR~I.
if((p_M1_stg1 <= 0.025)&(p_M2_stg1 <= 0.025)&(p_M3_stg1 <= 0.025)){
a1=1
}
if((p_M1_stg1 <= 0.025)&(p_M2_stg1 <= 0.025)&(p_M3_stg1 > 0.025)){
a1=2
}




if((p_M1_stg1 > 0.025)&(p_M2_stg1 <= 0.025)&(p_M3_stg1 <= 0.025)){
a1=4
}
if((p_M1_stg1 <= 0.025)&(p_M2_stg1 > 0.025)&(p_M3_stg1 > 0.025)){
a1=5
}
if((p_M1_stg1 > 0.025)&(p_M2_stg1 <= 0.025)&(p_M3_stg1 > 0.025)){
a1=6
}
if((p_M1_stg1 > 0.025)&(p_M2_stg1 > 0.025)&(p_M3_stg1 <= 0.025)){
a1=7
}





# IX. Evaluation of the MCP-Mod at every trial #
#################################################
# 1. Evaluate PoC establishment (PoA evaluation)
} # This is the end of i loop (see #1#).
)
##########################################
# X. Evaluation summary of L trials. #
##########################################
### MCP-Mod Hypothesis: no-response curve.
### MVT based ###







Note: The rest of program is omitted as the same coding is used for the other Emax,
quadratic, and logistic data. For the different data-generation code, see Appendix A.1.
79




### This program performs Establishment of PoC.
### Note: The total sample size in Study 2 are designed to be similar to that in Study 1.
### Equal sample sizes in Study 1 are set to be 75. For the other simulations,
### This number must be replaced to 10, 25, or 50. Equal sample sizes in Study 2
### must be also replaced accordingly.
library(mvtnorm)
############################
# I. planning a trial #
############################
# Number of simulated trials.
L <-10000
# number of the candidate D-R models.
m<-3
# number of adaptation choices in Stage 2.
adpt.L<-4
# (adpt.L choices x k+1 doses) design matrix for dose adaptation in Stage 2.
Z<-matrix(c(1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1),nrow=adpt.L)
tZ<-t(Z)
# Matrix for associating PoC results in Stage 1 with adaptations in Stage 2.
J<-matrix(c(1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1),ncol=m)
### Model Specification, Standardizing Models, and Empty Matrices for Evaluation ###
## 1. Obtain optimal regression coefficients (c_opt). ##
# maximize the power of the test == non-centrality parameter with regulatory condition.
# Using ragranges, we solve the formula and obtain c_opt vector.
# Maximum effect size.
delta.max<-0.6




compute_emax_c1_opt_m1 = function(kandP, n_stg, doses_stg) {
# Identity matrix of the number of dose size.
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
# Identity matrix of the number of patients/group size.
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### I. Standardized Emax Model.

























compute_quad_c1_opt_m2 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### II. Standardized quadratic Model.
























compute_logis_c1_opt_m3 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### III. Standardized Logistic Model.
























compute_cr1 = function(doses_stg, samples){









## 2. Find the critical value for PoC test H0 ###
# Refer to ’UsingMvtPackage.pdf’.
# The decision rule: use the best contrasts for computing the test statistic (Tmax).
# compute the critical value for the H0 test.
# Note: the linear contrast matrix under H0 is C1.
V1<-diag(1/n_stg1)
df1<-N1-k1andP




























### Stage 2 setting ###
# sample size per group for each adaptation choice.
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# Dose combination is the same as aI in ADTARI #
n0_stg2 <- 75 # Input sample size for Placebo
n2_stg2 <- 75 # Input sample size for treatment 2 (d=0.2)
n3_stg2 <- 75 # Input sample size for treatment 3 (d=0.6)
n4_stg2 <- 75 # Input sample size for treatment 4 (d=1.0)
# set sample sizes for each fixed dose combination in Stage 2.
n_stg2<-c(n0_stg2,n2_stg2,n3_stg2,n4_stg2) # For b_V fixed dose combination.
doses_stg2<-c(0,0.2,0.6,1.0)
#################################################################
# Note: For the other three fixed two-stage designs,
# the following sample sizes and/or doses are used in Stage 2.
#
# <Fixed two-stage design "aII">
# n0_stg2 <- 75 # Input sample size for Placebo
# n1_stg2 <- 75 # Input sample size for treatment 1 (d=0.05)
# n2_stg2 <- 75 # Input sample size for treatment 2 (d=0.2)




# <Fixed two-stage design "aIII">
# n0_stg2 <- 75 # Input sample size for Placebo
# n1_stg2 <- 75 # Input sample size for treatment 1 (d=0.05)
# n2_stg2 <- 75 # Input sample size for treatment 2 (d=0.2)




# <Fixed two-stage design "aIV">
# n0_stg2 <- 60 # Input sample size for Placebo
# n1_stg2 <- 60 # Input sample size for treatment 1 (d=0.05)
# n2_stg2 <- 60 # Input sample size for treatment 2 (d=0.2)
# n3_stg2 <- 60 # Input sample size for treatment 3 (d=0.6)






# k + 1 in Stage 2 (# of treatment doses and the placebo).
k2andP=length(doses_stg2)
#===================================================================================






# Compute Critical Values for Global PoC test.#
chi_df4_p975L<-qchisq(p=0.975, df=4, ncp=0, lower.tail = TRUE, log.p = FALSE)
GH_Mi_critValp975L<-exp(-(chi_df4_p975L)/2)
### A. Constant Data-Generating Function ############################################
#####################################
# II. Stage 1: Data Generating #
#####################################
### Prepare the empty matrices to fill the results for evaluation (see #IV#) ###
# for Stage 1
ps_stg1 = array(c(0),dim=c(4,L))
# for Stage 2
ps_stg2.noWt = array(c(0,0,0,0),dim=c(4,L))
# column 1: M1 p-value for H(s,1) using a univ. T-dist,
# column 2: M2 p-value for H(s,2) using a univ. T-dist,
# column 3: M3 p-value for H(s,3) using a univ. T-dist,
# column 4: mvt.prob1.
# Note: s=1, 2 (stage).
# T-stats for model 1, model 2, model 3 and Tmax.
Ts_stg1 = array(c(0,0,0,0),dim=c(4,L))
Ts_stg2.noWt = array(c(0,0,0,0),dim=c(4,L))
PoC_Gps.noWt = array(c(0,0,0,0),dim=c(4,L)) # for Global Tests.
# column 1: product of two (pVal from MVT).
# Results of L trials for Stage 1 and adaptive treatment decision "a" or "g".
H0_result1<-matrix(rep(0,L*3),ncol=3)
# Results of L trials for Stage 2,the number of models in Stage 2.
H0_result2.noWt<-matrix(rep(0,L*1),ncol=1)
# Results of L trials for Global Tests.
H0_resultG.noWt<-matrix(rep(0,L*6),ncol=6)
# column 1: overall global test based on MVT.
# column 2: global test on M1.
# column 3: global test on M2.
# column 4: global test on M3.
# column 5: Model # of the best model (the most significant model among M1,2,and 3).
# column 6: 1 if the best Model is significant.
### Dataset ’trial’ ###
# 1. Empty vectors& columns for dataset and specification.
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# stage 1 #
simul.time<-
system.time(for(l in 1:L){
# Empty data matrix to fill samples using the data generating function.
mydata1<-matrix(0,nrow=n_stg1[1],ncol=k1andP)
# Fill 1 if PoC is rejected for the model with the smallest p-value in the lth trial.
# To fill mean value mu0 of response Y for each dose group.
mu0<-c(rep(0,k1andP))
# To fill std.dv value sd0 of response Y for each dose group.
sd0<-c(rep(0,k1andP))
## 3. Draw sample size of nj for dose group j in the lth trial.##
for(j in 1:k1andP){
# std.dv of Y for dose j group are equally sd0=1.478.
sd0[j]<-1.478

















# III. Stage 1: Run the MCP-Mod #
#####################################
# analyzing a trial
# stage 1 #
## 4. Obtain the test stat w/ the best contrasts (c1_opt_m) ’Tmax_m’##
# Test statistic function. #
T1<-function(c){t(c)%*%mymean1/(s1*sqrt(t(c)%*%(solve(diag(n_stg1)))%*%c))}
# Test statistic T_m vector.#
T_m_stg1<-matrix(rep(0,m),nrow=1)
for(j in 1:m){













# IV. Evaluation of the MCP-Mod at every trial in Stage 1 #
############################################################
## 5. Test H0: the dose-response curve is flat ###
### Overall PoC test using MVT of m models in Stage 1.
### Note: this is using the critical value q_stg1.





### Individual models are tested based on a univariate t-distribution.
p_M1_stg1<-pt(T_M1_stg1, df1, lower.tail = FALSE, log.p = FALSE)
p_M2_stg1<-pt(T_M2_stg1, df1, lower.tail = FALSE, log.p = FALSE)
p_M3_stg1<-pt(T_M3_stg1, df1, lower.tail = FALSE, log.p = FALSE)
ps_stg1[,l]= c(p_M1_stg1,p_M2_stg1,p_M3_stg1,mvt.prob1)
Ts_stg1[,l] = c(T_m_stg1,T_max1) # T-stats for model 1, model 2, model 3 and Tmax.
#####################################
# V. Check the results of Stage 1 #
#####################################
# Check the result of Stage 1.
### ’a1’ uses the result of individual D-R testings.
if((T_M1_stg1 > q_stg1)&(T_M2_stg1 > q_stg1)&(T_M3_stg1 > q_stg1)){
a1=1
}
if((T_M1_stg1 > q_stg1)&(T_M2_stg1 > q_stg1)&(T_M3_stg1 <= q_stg1)){
a1=2
}




if((T_M1_stg1 <= q_stg1)&(T_M2_stg1 > q_stg1)&(T_M3_stg1 > q_stg1)){
a1=4
}
if((T_M1_stg1 > q_stg1)&(T_M2_stg1 <= q_stg1)&(T_M3_stg1 <= q_stg1)){
a1=5
}
if((T_M1_stg1 <= q_stg1)&(T_M2_stg1 > q_stg1)&(T_M3_stg1 <= q_stg1)){
a1=6
}
if((T_M1_stg1 <= q_stg1)&(T_M2_stg1 <= q_stg1)&(T_M3_stg1 > q_stg1)){
a1=7
}
if((T_M1_stg1 <= q_stg1)&(T_M2_stg1 <= q_stg1)&(T_M3_stg1 <= q_stg1)){
a1=8
}
# The result of Stage 1 into H0_result1 matrix.
H0_result1[l,2]=a1
#########################################################




#element-by-element operations on the weight and contrast vectors.
df2<-N2-k2andP










# 3. Fill the data from a data-generating function in Stage 2.
for(j in 1:k2andP){
#for(l in 1:n_stg2[j]){



















# VII. Stage 2: Run the Extended MCP-Mod #
##############################################
# analyzing a trial
# stage 2 #
## 4. Obtain the test stat w/ the best contrasts (c2_opt_m) ’Tmax_m’##
# Test statistic function. #
T2<-function(c){t(c)%*%mymean2/(s2*sqrt(t(c)%*%(solve(diag(n_stg2)))%*%c))}


















# VIII. Evaluation of the MCP-Mod at every trial in Stage 2 #
##############################################################
## 5. Test H0: the dose-response curve is flat ###
### Non weighted results using the critical value q_stg2.
delta.s2.noWt<-rep(0,length(subT.s2.noWt))






### Individual models are tested based on a univariate t-distribution.
p_M1_stg2.noWt<-pt(T_M1_stg2.noWt, df2, lower.tail = FALSE, log.p = FALSE)
p_M2_stg2.noWt<-pt(T_M2_stg2.noWt, df2, lower.tail = FALSE, log.p = FALSE)




# IX. Evaluation of the MCP-Mod at every trial #
#################################################
# 1. Evaluate PoC establishment (PoA evaluation)
## Global Tests without Weights ##




















} # This is the end of i loop (see #1#).
)
##########################################
# X. Evaluation summary of L trials. #
##########################################
### MCP-Mod Hypothesis: no-response curve.
### =>If rejected, at least one of (M1, M2 M3) is significant.
### MVT based ###
## Stage 1 ##
PoA_stg1_MCPMod.MVT<-mean(H0_result1[,1])
PoA_stg1_MCPMod.MVT
## Stage 2 without Weights ##
PoA_stg2_ExMCPMod.MVT.noWt<-mean(H0_result2.noWt[,1])
PoA_stg2_ExMCPMod.MVT.noWt
## Global Test by Fisher’s Combination Test ##
PoA_Global_ExMCPMod.MVT.noWt<-mean(H0_resultG.noWt[,1])
PoA_Global_ExMCPMod.MVT.noWt








Note: The rest of program is omitted as the same coding is used for the other Emax,
quadratic, and logistic data. For the different data-generation code, see Appendix A.1.






library(gplots) # for colorpanel()
library(lattice) # for levelplot()
### function to compute minimum eigen value for a placebo + 4 treatment doses.
get_eigen.k4 = function(len, s, sgn) {
d <- seq(1/(len-1), 1.0, len = len-1)
Nd<-length(d)





d1<-(c(0, d[k], d[j], d[i], d[u]))
cr1<-compute_cr1(d1, s)
data[k, j-1, i-2, u-3]<-min(eigen(cr1)$values)




### function to compute minimum eigen value for a placebo + 3 treatment doses.
get_eigen.k3 = function(len, s, sgn) {













get_eigen.k3.log = function(len, s, sgn) {






d1<-(c(0, d[k], d[j], d[i]))
cr1<-compute_cr1(d1, s)






### function to compute minimum eigen value for a placebo + 2 treatment doses.
get_eigen.k2 = function(len, s, sgn) {












### function to compute minimum eigen value for a placebo + 1 treatment doses.
get_eigen.k1 = function(len, s, sgn) {











### Model Specification, Standardizing Models ###





compute_emax_c1_opt_m1 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### I. Standardized Emax Model.





















compute_quad_c1_opt_m2 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### II. Standardized quadratic Model.

























### III. Standardized Logistic Model.
























































for(i in 1:N) {min.ev.k1[i]<-min(get_eigen.k1(i*step, s, 1))}
for(i in 1:N) {max.ev.k1[i]<-max(get_eigen.k1(i*step, s, -1))}
for(i in 1:N) {min.ev.k2[i]<-min(get_eigen.k2(i*step, s, 1))}
for(i in 1:N) {max.ev.k2[i]<-max(get_eigen.k2(i*step, s, -1))}
for(i in 1:N) {min.ev.k3[i]<-min(get_eigen.k3(i*step, s, 1))}
for(i in 1:N) {max.ev.k3[i]<-max(get_eigen.k3(i*step, s, -1))}
for(i in 1:N) {min.ev.k4[i]<-min(get_eigen.k4(i*step, s, 1))}










## counterexample: dose interval is fixed as 1.0/5=0.2 between doses.
# k=1 #
ev<-c()
for(i in 1:10) {
# step=dose interval.
step<-10^(-i)









for(i in 1:10) {
step<-10^(-i)








for(i in 1:10) {
step<-10^(-i)
# placebo and 3 doses. <- A specific dose combination.







for(i in 1:10) {
step<-10^(-i)
d<-c(0, step, 2*step, 3*step, 4*step)





### level plots ###
# Example I : Placebo and Three Treatment Doses #
# 20 potential treatment doses from 0.05 to 1.0.
len<-21
s<-20
# data for placebo and 3 doses.
data<-get_eigen.k3.log(len, s, 1)
# for axis labels.
d.level<-c(seq(1/(len-1), 1.0, len = len-1))
### Each subject has Stage 1, Stage 2, and Global results in the dataset







main="Min(Eigenvalue) for Placebo and Three doses, d3=1.0",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the smallest e.v. of R for Placebo and 3 trt doses with d3=1.0.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.95",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the smallest e.v. of R for Placebo and 3 trt doses with d3=0.95.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.90",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the smallest e.v. of R for Placebo and 3 trt. doses with d3=0.90.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.85",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.85.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.80",
sub="with log10 scales", xlab="d1", ylab="d2")
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### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.80.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.75",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.75.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.70",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.70.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.65",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.65.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.60",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.60.







main="Min(Eigenvalue) for Placebo and Three doses, d3=0.55",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.55.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.50",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.50.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.45",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.45.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.40",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.40.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.35",
sub="with log10 scales", xlab="d1", ylab="d2")
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### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.35.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.30",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.30.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.25",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.25.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.20",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.20.






main="Min(Eigenvalue) for Placebo and Three doses, d3=0.15",
sub="with log10 scales", xlab="d1", ylab="d2")
### Log10 of the Smallest e.v. of R for Placebo and 3 trt. doses with d3=0.15.
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A.5 WEIGHTED CORRELATION MATRICES USING DIFFERENT






# function to get rid of all-zero rows.
fun2 = function(MATRIX) {
P = nrow(MATRIX);
NA.row = rep(NA,P) ;
for (i in 1:P) {
if ((is.na(sum(MATRIX[i,]))) || (sum(MATRIX[i,])) == 0) {
NA.row[i] = -i}
}
if(length(na.exclude(NA.row))>=1){new = MATRIX[na.exclude(NA.row), ]
}
else { new=MATRIX }
return(new)
}
# function to get rid of 0 value in partition candidates.
dropZero<-function(v) {
r<-c()





# function only to leave non-duplicate partition sets.
uniqueAdd<-function(parts, p) {






for (i in 1:length(pm[,1]))







# function to simulate all partition candidates given
# ’the number of results in Stage 1’ (=val) and





for (i in 1:length(candidates[1,])) {
part<-dropZero(candidates[1:num, i])
if ((sum(part) == val) && (length(part) == num)) {
for (j in 1:length(perms[,1])) {
u<-c()










# function to make a design matrix Z consisting of L rows
# (=number of adaptation choices g);
# a sub-matrix of the full design matrix full.Z.
subMat<-function(full.Mat, gs) {
Mat.L<-length(gs)
Mat<-c() # rth row vector of ’Mat’ matrix.





# function to build a full design matrix full.Z
build.full.Z<-function(n, p.ds) {
# number of vector containing all potential doses.
orig<-1
# number of vectors allowing 1 dose dropped
# from the set of potential doses.
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drop.1<-length(combinations(4,1)[,1])
# number of vectors allowing 2 doses dropped
# from the set of potential doses.
drop.2<-length(combinations(4,2)[,1])
if (n==1) {
full.Z<-matrix(c(1), nrow = orig+drop.1, ncol = p.ds)
# all possible design matrix Z’s of full. Z.





# how to drop 2 doses out of 4 potentials.
cdp2<-combinations(4,2)
full.Z<-matrix(c(1), nrow =orig+drop.1+drop.2, ncol = p.ds)
for (i in 1:drop.1){
full.Z[orig+i,i]=0
}
for (i in 1:drop.2){
full.Z[orig+drop.1+i,1+cdp2[i,1]]=0 # 1st dose to drop.






# End: Helper Functgions
#===================================================================================
#===================================================================================
# Models and unweighted contrast vectors
#===================================================================================
### Model Specification, Standardizing Models, and Empty Matrices for Evaluation ###





compute_emax_c1_opt_m1 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### I. Standardized Emax Model.























compute_quad_c1_opt_m2 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### II. Standardized quadratic Model.




















compute_logis_c1_opt_m3 = function(kandP, n_stg, doses_stg) {
Ident1.s1<-matrix(rep(1,kandP),ncol=1)
Ident2.s1<-matrix(rep(1,n_stg[1]),ncol=1)
### III. Standardized Logistic Model.


























# END: Models and unweighted contrast vectors
#===================================================================================
#===================================================================================
# Compute weight matrix
#===================================================================================
# for given;
# Z: Adaptation design matrix
# adpt.a: Partition vector where the number of PoC results in Stage 1
# are partitioned into L adaptations of Z
# g: Adaptation choice defined in Z (g=1,...,L)
W_a<-function(g, adpt.a, tZ) {
W_g<-adpt.a[g] * tZ[,g,drop=F] %*% c(1,1,1)
# We fix a1=1 in W_a(g,a1) of this simulation. --
# all probabilities for testing model m is set to be 1 regardless of its
# testing result in Stage 1. if that changes, the code needs to be rewritten.
return(W_g)
}





for (i in 1:gmax) {







for (i in 1:length(Wg[,1])) {










# END: Compute weight matrix
#===================================================================================
#===================================================================================
# Compute weighted correlation matrix
#===================================================================================
#==============================================
# compute the correlation matrix from
# dose vector: doses_stg
# samples: samples
# weight matrix: W_g
compute_wt_cr2 = function(doses_stg, samples, W_g){


















C2<-matrix(Wc2_opt, nrow=m)# under H0.
cv2<-C2%*%V2%*%t(C2)
dv2<-t(1/sqrt(diag(cv2)))




# END: Compute weighted correlatrion matrix
#===================================================================================
#===================================================================================
# SCRIPT: Going through (traverse) space and evaluate
#===================================================================================
#==============================================
# compute weight matrices for all choices
step<-0.05
doses<-c(0, step, 2*step, 3*step, 4*step)
#doses<-c(0, 0.2, 0.5, 0.8, 1.0)
samples<-20
# the number of PoC results in Stage 1 given the number of candidate dose-response
# models is m.
a.stg1<-2^m
# placebo and candidate doses.
poten.doses<-5
max.L<-5 # the number of all gs of full.Z.
# full Z matrix.
full.Z<-matrix(c(1), nrow = max.L, ncol = poten.doses)
















#for (num.g in 1:max.L) {
for (num.g in 1:min(max.L,a.stg1)) {
combs<-combinations(max.L, num.g)
# the number of k dose combinations where ’k = # of doses to use’.
num.comb.g<-length(combs[,1])
mevs2<-c()
for (j in 1:num.comb.g) {
Z<-subMat(full.Z, combs[j,])
# all partitions (related to ADTAR rule mapping result a1
# (in a.stg1) to g (in adpt.L of design matrix Z))
adpt.L<-num.g
p<-buildParts(a.stg1, adpt.L)
for (i in 1:length(p[1,])) {
adpt.a<-p[,i]
for (g in 1:length(adpt.a)) {
fullWg<-computeWg(g, adpt.a, Z)



















# the minimum of min(eigenvalue) of WtR matrices
# over all possible Z matrices given a set (doses).
#print(ZandMEv$minMEv)
# list the minimums of min(eigenvalue) of WtR matrices for each length L





# all min(eigenvalue) of WtR matrices sorted by the length L of design




### compute minimum eigen value of weighted Rs for various sets of
# placebo + 4 potential doses.
all_doses.k4 = function(len) {
len<-len+1
d <- seq(1/(len-1), 1.0, len = len-1)
print(c(0,d))
Nd<-length(d)
# data<-array(c(Inf),dim=c(Nd-3, Nd-3, Nd-3, Nd-3))





#print(c(k, j, i, u))





data[k, j, i, u]<-minEv








file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp1d_05Jul10.Rdata")




file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp1d_05Jul10.Rdata")
# min.eigens allowing 1 dose to be dropped (dose step size=20).
result.stp20.drp1<-all_doses.k4(20)
min(result.stp20.drp1)
# Store the results #
save(full.Z, result.stp5.drp1, result.stp10.drp1, result.stp20.drp1,
file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp1d_05Jul10.Rdata")
#==============================================
### NEXT EXPERIMENT: allows 1 or 2 doses excluded by ADTAR.
#simple test case first.
# one row drops two doses in the current full.Z (row length =5).
110
full.Z[2,3]=0
# min.eigens allowing 1 or 2 doses to be dropped (dose step size=10).
case1.stp10.drp2<-all_doses.k4(10)
min(case1.stp10.drp2)
# Store the results #
save(full.Z, case1.stp10.drp2,
file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp2d_Case1_05Jul10.Rdata")
#now the full experiment.
# make a new full.Z.
# placebo and candidate doses (potential doses).
poten.doses<-5
# contains all the sets of doses where ’up to 2 doses’ are dropped
# from 5 potentials.
full.Z<-build.full.Z(2,poten.doses)
# the number of all gs of full.Z.
max.L<-length(full.Z[,1]) # max.L<-orig+drop.1+drop.2
# I. generate all possible design matrix Z’s for the new full Z and
# get min.eigens allowing 1 dose or 2 doses to be dropped (dose step size=5).
result.stp5.drp2<-all_doses.k4(5)
min(result.stp5.drp2)
# Store the results #
save(full.Z, result.stp5.drp2,
file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp2d_11Jul10.Rdata")
# II. generate all possible design matrix Z’s for the new full Z and
# get min.eigens allowing 1 dose or 2 doses to be dropped (dose step size=10).
result.stp10.drp2<-all_doses.k4(10)
min(result.stp10.drp2)
# Store the results #
save(full.Z, result.stp5.drp2, result.stp10.drp2,
file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp2d_11Jul10.Rdata")
# III. generate all possible design matrix Z’s for the new full Z and
# get min.eigens allowing 1 dose or 2 doses to be dropped (dose step size=20).
result.stp20.drp2<-all_doses.k4(20)
min(result.stp20.drp2)
# Store the results #
save(full.Z, result.stp5.drp2, result.stp10.drp2, result.stp20.drp2,
file = "//10.0.0.3/yoko’s data/R_Code/2ndPaperR/MinEvs_ADTAR_Drp2d_11Jul10.Rdata")
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